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ABSTRACT: Failure to resolve inflammation underlies many
prevalent pathologies. Recent insights have identified lipid
mediators, typified by lipoxins (LXs), as drivers of inflammation
resolution, suggesting potential therapeutic benefit. We report the
asymmetric preparation of novel quinoxaline-containing synthetic-
LXA4-mimetics (QNX-sLXms). Eight novel compounds were
screened for their impact on inflammatory responses. Structure−
activity relationship (SAR) studies showed that (R)-6 (also
referred to as AT-02-CT) was the most efficacious and potent
anti-inflammatory compound of those tested. (R)-6 significantly
attenuated lipopolysaccharide (LPS)- and tumor-necrosis-factor-α
(TNF-α)-induced NF-κB activity in monocytes and vascular
smooth muscle cells. The molecular target of (R)-6 was investigated. (R)-6 activated the endogenous LX receptor formyl peptide
receptor 2 (ALX/FPR2). The anti-inflammatory properties of (R)-6 were further investigated in vivo in murine models of acute
inflammation. Consistent with in vitro observations, (R)-6 attenuated inflammatory responses. These results support the therapeutic
potential of the lead QNX-sLXm (R)-6 in the context of novel inflammatory regulators.
■ INTRODUCTION
Inflammation is a vital physiological response to infection1 or
trauma.2 Implicit in effective inflammation is a response limited
in time and space and coupled to repair, which promotes return
to homeostasis (catabasis).3 In contrast, unresolved chronic
inflammation leads to fibrosis, tissue scarring, and, ultimately,
organ failure.4 The resolution of inflammation is a prerequisite
for homeostasis and tissue integrity maintenance,5 and it is now
understood that chronic, insidious inflammation is an important
driver of numerous prevalent conditions including arthritis,6
atherosclerosis, diabetes, and associated vascular complica-
tions.7 Efforts to repurpose existing drugs and to develop new
ones for the treatment of such diseases are ongoing.8 To date,
the focus has typically been on anti-inflammatory strategies9
and, while these show efficacy, there are challenges regarding the
inevitable compromise of innate host defense strategies upon
chronic administration.10
The LXs (an acronym for lipoxygenase interaction products)
are endogenously generated eicosanoids originally isolated from
human leukocytes.11 LX biosynthesis is initiated during the
course of an inflammatory response,12 and LXs promote the
resolution of inflammation by multiple convergent mechanisms,
including inhibition of polymorphonuclear cell (PMN) chemo-
taxis, monocyte adhesion and transmigration,13 macrophage
phagocytosis,14 and suppression of fibrosis.15 In addition to
attenuating acute inflammatory responses, we have recently
shown that LXs attenuate chronic inflammatory conditions,
including renal fibrosis16 and the micro-17 and macrovascular18
complications of diabetes.19
Analysis of lipid mediator production over the course of self-
limiting inflammation has led to the identification of additional
families of mediators20 (including resolvins, protectins,21 and
maresins22) with complementary bioactions leading to the
collective term “specialized proresolving lipid mediators”
(SPMs).23 Importantly, responses to SPMs are not coupled to
compromised host defense.24 The discovery of SPMs25 and their
bioactions and molecular targets26 has led to the proposal that
these may be lead compounds for therapies based on promoting
resolution.27
Deficits in the generation of endogenous LXs have been
associated with several chronic inflammatory diseases, including
asthma,28 arthritis,29 and cystic fibrosis.30 However, there are
major obstacles to the application of LXs as pharmacological
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agents. LXA4 is rapidly metabolized in vivo by oxidation at C15,
reduction of the C13−C14 double bond,31 ω-oxidation at
C20,32 and β-oxidation at C-3.12a LXA4 also has chemical
stability issues, as it isomerizes to a mixture of double-bond
isomers, including the corresponding E,E,E,E- or 11-trans-LXA4
in the presence of light, and decomposes in the presence of a
strong acid.12a Therefore, exploitation of the therapeutic
potential of LXs has driven the design and synthesis of small
molecules, collectively named “synthetic-LXA4-mimetics”
(sLXms).33
Mimetics have been designed to retain key functional groups
required for activity. Analogues with modifications to the top
C1−8 chain have been reported and are more resistant to β-
oxidation.12a There are many analogues reported that have
modified the lower C15−20 chain, which are equipotent or
more potent than native LXA4 (1) but more resistant to C15
Figure 1. Native LXA4 (1) and synthetic-LXA4-mimetics (2−8).
Scheme 1. Synthesis of Coupling Partner 14 and Cross-Metathesis to Form 17
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dehydrogenation and C20 oxidation.33 We have focused on
modifying the triene core, replacing it with aromatic or
heteroaromatic rings, to slow down enzymatic reduction of
the C13−14 double bond and prevent double-bond isomer-
ization. We reported the first asymmetric synthesis of the benzo-
mimetic (2)34 and more recently the pyridino-,35 oxazolo-, and
imidazolo-containing mimetics (3−5),36 all displaying similar
bioactivity to LXA4 (1), with the imidazolo-mimetic proving to
be the most potent, significantly attenuating lipopolysaccharide
(LPS)-induced NF-κB activity and attenuating pivotal proin-
flammatory cytokine secretion.36 Here, we report the asym-
metric preparation and biological evaluation of quinoxaline-
containing LXA4 mimetics (QNX-sLXms) (6−8) (Figure 1).
These novel quinoxaline mimetics, like our current lead
imidazolo-containing mimetic (5), possess two nitrogens in the
heterocyclic system with enhanced potential to engage in
hydrogen bonding with the receptor and potentially achieve
greater potency than LXA4. Here, we describe the stereoselective
preparation of both epimeric alcohols on the lower chain with
small variations in lower alkyl chain length as well as our
investigation to probe the impact of such modifications on
biological activity. Biological activity has been assessed in the
context of inflammatory responses, including NF-κB activity,
cytokine release, and lactate dehydrogenase (LDH) secretion in
vitro. Target receptor engagement (ALX/FPR2) has been
investigated by determining intracellular calcium mobilization.
The efficacy of the lead compound has been investigated in an in
vitromodel of phagocytosis as well as in murine models of acute
peritonitis and paw swelling. The relative pharmacodynamic
(PD) properties of the compounds have been compared to
LXA4 in an effort to identify the lead compound. These analyses
combined data from concentration−response curves (potency,
efficacy, and slope) and identified compounds with enhanced
potency to LXA4.
■ RESULTS
Synthetic Chemistry. The first synthetic route investigated
for synthesizing the analogues was similar in approach to that
used previously for the synthesis of the benzo-lipoxin mimetic
(2). Starting with 2-chloroquinoxaline (9), ketone (11) was
synthesized in 72% yield using Antonchick’s cross-dehydrogen-
ative coupling procedure using hexanal (10) with (bis-
(trifluoroacetoxy)iodo)benzene and trimethylsilyl azide,
Scheme 1.37 Attempts to lithiate (9) at the 1-position with
LDA, LiTMP, and TMPMgCl−LiCl and a subsequent quench
with various electrophiles were unsuccessful. Similarly, Minisci
reactions under various conditions failed to furnish any of the
desired product 11. Our first attempts to form the quinoxaline to
the alkene bond involved the Pd-catalyzed Heck reaction with
terminal alkene 12,38 but despite using a variety of palladium
sources and ligands, the desired product 13 was not formed. A
test reaction using methyl acrylate was carried out, and although
the product was isolated in low yields, this indicated that the
quinoxaline component was undergoing oxidative addition, but
there was a problem with the low reactivity of the alkene
reactant. Therefore, a new route to the analogues was developed
invoking a Grubbs cross-metathesis to form the trans-alkene
motif. The vinyl quinoxaline intermediate 15 was synthesized in
two steps, by first reducing ketone 11 using sodium borohydride
in 58% yield and then performing a Pd-catalyzed Stille coupling
with tributylvinyltin, which proceeded in an 88% yield. We
found that a direct Stille coupling on the quinoxaline ketone 11
led to an unstable product, which rapidly decomposed with
similar instability issues of similar compounds having been
previously reported.39 A Grubbs cross-metathesis was carried
out employing the Hoveyda−Grubbs 2nd generation catalyst,
and product 17 was stereoselectively obtained in a low yield of
26%, primarily due to difficulties with product purification. This
limits the applicability of this route to scaling to bulk synthesis
levels.
An alternative route to the formation of mimetics of types 6−
8 was investigated, this time featuring a Suzuki cross-coupling
reaction as the key arene to alkene-bond-forming reaction,
coupling the quinoxaline component 14 to the boronic ester 18.
The synthesis of the boronic ester coupling partner 18 has been
recently reported by us, but the combined low yielding nature of
the last two steps, a Seyferth−Gilbert homologation (68%) and
a hydroboration using pinacolborane catalyzed by Schwartz’s
Scheme 2. Synthesis of Vinyl Boronate 18
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reagent (34%), was limiting.36 Starting from commercially
available 2-deoxy-D-ribose 19, which has the desired stereo-
chemistry in place, an acetonide protection to form 20 was
carried out followed by a Wittig reaction and alkene reduction
using Pd/C to prepare intermediate 22 (Scheme 2). The
formation of the aldehyde 23 was optimized using a 2,2,6,6-
tetramethylpiperidine 1-oxyl radical (TEMPO)-catalyzed oxi-
dation, which proceeded in a 74% yield. A Takai reaction with
the dichloromethyl pinacol boronate reagent 24,40 chromium
chloride, and lithium iodide proceeded to generate the boronate
coupling partner 18 in a satisfactory 68% yield.
The asymmetric reduction of the quinoxaline ketone 11 was
first attempted using the RuCl[(R,R)-Tsdpen][p-cymene]
catalyst in a transfer hydrogenation with formic acid and
triethylamine, but low enantioselectivities of 66% were
observed. Hydrogenation using Noyori’s catalyst (R,R)-
RuCl2[xylBinap]DAIPEN in the presence of potassium tert-
butoxide and triisopropyl borate proceeded giving excellent
enantioselectivity of 99% for both enantiomers, albeit in
moderate yields of 40 and 54% for the (R)- and (S)-
enantiomers, respectively; see Scheme 3. The configuration of
the enantiomers was confirmed by Mosher’s ester analysis41 and
matched that predicted by Noyori’s transition states.42 The
Suzuki coupling reaction between aryl chloride (14) and vinyl
boronate (18) was then attempted using Pd(PPh3)4, but this
failed to furnish any of the desired products. Pd(dppf)Cl2 has
been reported to be successful in the Suzuki coupling of π-
deficient hetero-aryl chlorides,43 but our optimized catalyst
system used bis(benzonitrile)palladium dichloride together
with the ligand 1,4-bis(diphenylphosphino)butane (dppb)
giving (1R)-11 in a 48% yield and the (1S)-product 11 with a
40% yield (Scheme 3). The acetonide group was removed by
reaction with camphorsulfonic acid in methanol, and the final
analogues (1R)-6 and (1S)-6were isolated in 65 and 83% yields,
respectively.
Using the same synthetic strategy, four further analogues
[(1R)-7, (1S)-7, (1R)-8, and (1S)-8] with varying lengths of
alkyl chain were synthesized to probe the effect this would have
on the binding to the receptor and thus biological activity
(Scheme 4). This gives a total of six QNX-sLXms, which, in
addition to the acetals (R)- and (S)-17, were subjected to
biological evaluation as described below.
Biological Evaluation. In Vitro Screening of QNX-sLXms
Identifies (R)-6 as the Lead Modulator of Inflammation.
Using an LPS-challenged human THP-1 monocyte cell line
stably expressing an NF-κB luciferase promoter reporter, the
anti-inflammatory bioactions of QNX-sLXms were explored, as
described previously.36 Our work (not shown) and the work of
others have shown ALX/FPR2 expression in THP-1 cells.44 For
screening purposes, the eight candidate compounds were
divided into four groups, based on their chemical structure, as
described in the “study design” (Figure 2).
Scheme 3. Asymmetric Hydrogenation of Quinoxaline Coupling Partner 11 and Syntheses of (R)- and (S)-6
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For all in vitro assays, we derived an aggregate “score” for each
compound to describe the pharmacodynamic (PD) profile
elicited relative to responses to LXA4, thus named the “relative
PD score”. This score reflects the maximal % of inhibition of
LPS-stimulated response (Imax) [or the maximal % of excitation
relative to the vehicle (Emax)], the half-maximal inhibitory or
excitatory concentration (IC50) or (EC50), and the slope of the
concentration−response curve [indicated as the Hill−Slope
(HS)] (Table S1).
QNX-sLXms Attenuate NF-κB Activity in Human Mono-
cytes. LPS-induced NF-κB-driven luciferase activity was
measured in response to all eight candidates (concentration
range: 1 pM to 1 μM). LXA4 (1), previously identified sLXms
[specifically, benzo-LXA4 (2) (1 pM) and imidazolo-LXA4 (5 or
AT-01-KG)], and the anti-inflammatory cortisol mimetic
dexamethasone (Dex; 1 μM) were used as positive controls
and/or reference compounds (Figure 3a).
The reference PD profile of LXA4 (1) showed an Imax of 24 ±
1% and an IC50 of 60 pM. We identified several “hits”: (R)-6
showed the best PD score (Imax = 38 ± 9%; IC50 = 25 pM; rel.
slope = 57; PD score = +5; p < 0.05). Its epimer, (S)-6, reduced
the luciferase activity to a lesser extent (approx. 25−35%) and in
amuch wider range (1 pM−1 μM) (PD score = +2; p < 0.0001).
In group C, both epimers [(R)-7, (S)-7] efficiently (by 30−
Scheme 4. Syntheses of Quinoxaline Mimetics (R)- and (S)-7 and (R)- and (S)-8 with Varied Alkyl Chain Lengths
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35%) and significantly (p < 0.05) decreased the NF-κB activity
but were the least potent of all candidates, as demonstrated by
IC50 in the “nM” range. In group D, [(R)-8, (S)-8] reduced the
activity by about 10−20%, thus showing a lower efficacy
compared to the other candidates (IC50 in the “pM” range). In
contrast, the least effective compounds were the acetonides (R)-
and (S)-17 (group A). In the absence of the LPS challenge, the
compounds did not have any effect on the NF-κB activity per se
(Figures 3 and S1).
For clarity, data presented in Figure 3 show the effect of (R)-6
and its epimer (S)-6 on LPS-stimulatedNF-κB luciferase activity
together with relevant controls. Further details of responses to
other compounds are provided in Figure S1, as detailed above.
Relative PD scores are supplied in Table S2.
Quinoxaline-Containing sLXms Hits Differentially Modu-
late Cytokine Release in Human Monocytes. To further test
the anti-inflammatory bioactions of the six most active
compounds (hits) out of the eight candidates, effects on
downstream targets of the NF-κB pathway were measured [IL-6,
IL-1β, IFN-γ (Figure S2), IL-10, IL-8, IL-12p70, tumor-
necrosis-factor-α (TNF-α) (Figure 4)], using multiplex
enzyme-linked immunosorbent assay (ELISA) analysis of the
supernatant from THP-1 monocytes treated with LPS with or
without sLXms.
QNX-sLXms from Group B, but not C and D, Abolish IL-6
Secretion. LPS significantly induced IL-6 secretion from
monocytes (basal secretion = 1 ± 0.1 pg/mL vs LPS-induced
release = 3584 ± 122 pg/mL). As previously reported,36 LPS-
stimulated IL-6 release was almost completely abolished by
LXA4 (1) (10 pM−100 nM) (p < 0.0001), displaying an Imax of
99± 1% and an IC50 of 1 pM (Figure S2bi). Similarly, 1 μMDex
abolished IL-6 levels (Imax = 98± 1%, p < 0.0001), whereas 1 pM
(2) attenuated IL-6 concentration to a lesser extent (Imax = 42±
3%, p < 0.001) (Figure S2ai). Both mimetics from group B
significantly (p < 0.001) reduced IL-6 release, with the (S)-
epimer performing better than the native compound, as shown
by the positive value of the PD score [relative to LXA4 (1)]. In
particular, (R)-6 displayed Imax = 84± 2%; IC50 = 1 pM; rel. slope
= 0.7; and PD score = −2 (Figure S2ci). The (S)-6 epimer
displayed Imax = 98 ± 1%; IC50 = 1 pM; rel. slope = 2.4; and PD
score = +2 (Figure S2di). On the other hand, mimetics from
groups C and D did not significantly attenuate IL-6 secretion
(negative PD scores, ranging from −4 to −8) (Figure S3).
QNX-sLXms (R)-6 from Group B Inhibits IL-1β Secretion.
LPS significantly induced IL-1β secretion (basal secretion = 2 ±
0.5 pg/mL vs LPS-induced release = 1162 ± 53 pg/mL) from
monocytes. As we previously demonstrated,36 LPS-stimulated
IL-1β release was almost completely abolished once again by
LXA4 (1) (10 pM−100 nM), displaying an Imax of 93−95 ± 1%
Figure 2. Rational design of QNX derivatives and subgrouping criteria. Strategies adopted to modify the structure of the native LXA4 compound (top-
right corner) to obtain eight derivatives. QNX-sLXms contain an ortho-disubstituted quinoxaline ring (top-left corner). Modifications to the “upper
chain” are highlighted in orange, while modifications to the “lower chain” are highlighted in green: based on this classification, the screening has been
carried out on four subgroups of candidates [A (precursor), B, C, and D].
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and an IC50 of 1 pM (p < 0.001) (Figure S2bii), as well as 1 μM
Dex (Imax = 86 ± 6%, p < 0.0001), whereas 1 pM (2) maximally
reduced secretion by 59 ± 4% (p < 0.0001) (Figure S2aii). The
(R)-epimer from groupB significantly (p < 0.0001) inhibited IL-
1β secretion but without outperforming LXA4 (1) (Imax = 73 ±
2%; IC50 = 1 pM; rel. slope = −0.03; PD score = −2) (Figure
S2cii); however, its epimer completely lost the protective effect
(PD score =−6) (Figure S2dii). Mimetics from groupsC andD,
although significantly (p < 0.05−0.001) attenuating IL-1β
secretion, did not outperform the parent compound (negative
PD scores of −3 and −4) (Figure S3).
All QNX-sLXms Tested Inhibit IFNγ Secretion. LPS
significantly induced THP-1 monocyte secretion of IFNγ
(basal secretion = 15 ± 2 pg/mL vs LPS-induced release =
146± 11 pg/mL). As shown,36 LPS-stimulated IFNγ release was
attenuated by LXA4 (1) (10 pM−100 nM), [Imax = 72 ± 4%;
IC50 = 1 pM (p < 0.001)] (Figure S2biii) as well as 1 μMDex (by
56 ± 2%, p < 0.01), whereas 1 pM (2) did not significantly alter
LPS-stimulated IFNγ release (Figure S2aiii). The (R)-epimer
from group B, (R)-6, significantly (p < 0.0001) inhibited IFNγ
secretion (Imax = 62 ± 1%; IC50 = 1 pM) (Figure S2ciii), while
the (S)-epimer reduced IFNγ secretion more efficiently but less
potently (Imax = 74± 4%; IC50 = 2 nM) (Figure S2diii). None of
these outperformed LXA4 (1). Interestingly, both epimers from
group C significantly (p < 0.0001) almost abolished IFNγ
secretion, by 85−90 ± 2−4%, IC50 = 1−2 pM, with the (R)-
epimer, (R)-7, outperforming the native compound (PD score =
+ 1). Both mimetics from group D, (R)- and (S)-8, although
significantly attenuating (p < 0.05−0.0001) IFNγ release, did
not perform better than the parent compound (negative PD
scores) (Figure S3).
For clarity, the effects of the native (1) and the lead
compound (R)-6 on all seven cytokines assayed are summarized
in Figure 4. The data presented in Figure S2 show the effect of
(R)-6 and its epimer (S)-6 only on LPS-stimulated “prototype”
inflammatory cytokines (IL-6, IL-1β, INFγ) released together
with the relevant controls. Data from the other compounds
investigated on these three key cytokines are shown in Figure S3
as detailed above. Relative PD scores are supplied in Table S3.
Notably, LPS-induced secretion of IL-8 was enhanced by 2.5-
fold (p < 0.001) by Dex (1 μM) (not shown), LXA4 1 (1 nM) as
well as (R)-6. Therefore, (1) and (R)-6were equally efficient but
more significantly potent than Dex in enhancing IL-8 release
(Figure 4).
Overall, (R)-6 was confirmed to be the most effective
candidate, downregulating the classical proinflammatory
Figure 3. Effect of series (6) of QNX-sLXms on LPS-induced NF-κB-driven luciferase activity in monocytes. A total of 1 × 105 THP-1 LUCIA
monocytes were pretreated for 30 min with sLXms, vehicle, or appropriate controls, at indicated concentrations in the presence (LPS-activated) or
absence (basal) of 50 ng/mL LPS. After 24 h, supernatants were collected andNF-κB-driven luciferase activity was assayed. (a) Single-point analysis of
the internal controls. (b) Concentration−response curves of reference compounds (1, 5) and QNX-sLXms. Data are expressed as %± SEM (n = 3) of
normalized luminescence unit relative to LPS-induced response. Best-fitting curves are indicated by black solid lines. Statistical analysis was carried out
using Student’s unpaired two-tailed t-test of the tested compound vs LPS (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001) or vs LXA4 1 (not
shown).
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Figure 4. Effect of QNX-sLXm lead compound (R)-6 on the whole panel of proinflammatory cytokine release in monocytes. A total of 1× 105 THP-1
LUCIA monocytes were pretreated for 30 min at indicated concentrations with LXA4 1 (i) or QNX-sLXm (R)-6 (ii). After 24 h from the subsequent
stimulation with LPS, supernatants were collected and a panel of seven proinflammatory cytokine levels was measured (IL-6, IL-1β, IFN-γ, IL-12p70,
IL-8, IL-10, TNF-α). Concentration−response curves show upregulated (blue), downregulated (red), or unmodified (black) cytokines. Statistical
analysis was carried out using Student’s unpaired two-tailed t-test of the tested compound vs LPS (ns, not significant; ****p < 0.0001).
Figure 5. Intrinsic cytotoxic profile of series (6) of QNX-sLXms. A total of 1× 105 THP-1 LUCIAmonocytes were treated for 24 h with QNX-sLXms,
vehicle, or appropriate controls (1 pM to 1 mM). After 24 h, supernatants were collected and LDH release was assayed. (a) Single-point analysis of
controls defines a “high” (red area), “moderate” (yellow area), and “low” (gray area) level of cytotoxicity. (b) Concentration−response and best-fitting
curves of (R)-6 and (S)-6. Data are expressed as % LDH release relative to LPS ± SEM (n = 3). Statistical analysis was carried out using Student’s
unpaired two-tailed t-test of the tested compound vs LPS (**p < 0.01; ***p < 0.001; ****p < 0.0001).
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cytokines (IL-6, IL-1β, and IFN-γ) and, interestingly, enhancing
secretion of IL-8 from monocytes, similar to controls (1) and
Dex.
In Vitro Safety Study of QNX-sLXms Identifies (R)-6 as a
Safe “Lead”Modulator of Inflammation. Lactate dehydrogen-
ase (LDH) release is a measure of plasma-membrane integrity
conventionally used to assay associated cell damage.45 More
recently, it has also been recognized as an important
inflammatory biomarker, alongside established markers includ-
ing CRP, IL-1β, and IL-6 in the context of cancer,46
pneumonia,47 and diabetic retinopathy48 models, as well as,
very recently, in COVID-19.49
We investigated the potential cytotoxicity of all candidate
sLXms by assaying LDH release.50 The response to LPS was
arbitrarily set to 100%, and values were expressed relative to this.
As previously reported by others, LPS provokes LDH release.51
The maximal LDH release was observed in response to Triton-
X-100 (approximately 3-fold higher than LPS-induced levels).
Ultimately, untreated cells defined the spontaneous cell release
thresholds. These three responses also defined the thresholds of
the LDH-associated level of toxicity, as displayed in Figure 5a.
Lead sLXm (R)-6 Displays a Safe Cytotoxic Intrinsic Profile.
In the absence of LPS challenge, all tested compounds displayed
a safe intrinsic profile, with the exception of acetonides (17),
which induced an LDH release significantly (p < 0.01) higher
than the spontaneous cell release. Interestingly, (R)-6, (R)-7,
and (S)-8 showed LDH levels significantly (p < 0.05−0.001)
lower than the vehicle, at the nM range. Additionally, Dex (1
μM), 2 (1 pM), or 5 (1 pM) did not display any significant
cytotoxic effect, with an LDH release comparable to that of the
vehicle (Figures 5 and S4).
Lead sLXm (R)-6 Attenuates LPS-Induced Extrinsic
Cytotoxicity. In cells stimulated with LPS, a 2-fold increase in
LDH release was observed compared to the baseline (from 49 to
100%). In the presence of (R)-6, cytoprotection was preserved
when challenged with LPS for 24 h, significantly (p < 0.001)
attenuating by 1.3- to 2.4-fold the LPS-induced toxicity (ranging
from 42± 4% at the lowest dose of (R)-6 up to 77± 10%, at the
highest). It is noteworthy that Dex (1 μM) did not reduce LPS-
induced LDH, as has been reported in similar in vitro systems by
others,52 when compared with in vivo observations53 (Figures 6
and S5).
Lead sLXm (R)-6 Displays a Safe “Activity−Toxicity” Index.
A postanalysis “safety study”was conducted on all QNX-sLXms.
For each tested compound, we calculated an in vitro “Safety
index” (Si) by relating its “anti-inflammatory half-maximal
activity” (the highest dose among the IC50 of the extrinsic LPS-
challenged phenotype: NF-κB activity, proinflammatory cyto-
kine, and LDH release) to its intrinsic “toxicity” (expressed as
the relative half-maximal LDH-associated cytotoxicity). The
generated Si is potentially predictive of a translational
“therapeutic” range: the higher the Si, the safer the molecule
is. As summarized in Table S4, Si values from all tested
compounds fall in a broad range (7−50). The lead compound
Figure 6. Extrinsic cytotoxic profile of series (6) of QNX-sLXms. A total of 1 × 105 THP-1 LUCIA monocytes were pretreated for 30 min with QNX-
sLXms, vehicle, or appropriate controls (1 pM−1 μM) and subsequently challenged for 24 h with 50 ng/mL LPS. After 24 h, supernatants were
collected and LDH release was assayed. (a) Single-point analysis of controls defines a high (red area), moderate (yellow area), and low (gray area) level
of cytotoxicity. (b) Concentration−response and best-fitting curves of (R)-6 and (S)-6. Data are expressed as % LDH release relative to LPS± SEM (n
= 3). Statistical analysis was carried out using Student’s unpaired two-tailed t-test of the tested compound vs LPS (*p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001).
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://doi.org/10.1021/acs.jmedchem.1c00403
J. Med. Chem. 2021, 64, 9193−9216
9201
(R)-6 displayed an “intermediate” index of 20, associated with
low cytotoxicity.
In summary, the lead compound tested for cytotoxicity
displayed safety within the pM to nM range, in the presence or
absence of LPS. These data are shown in Figure 5. Data from all
compounds tested are shown in Figure S4.
Given the impact on inflammatory responses reported above,
subsequent in vitro and in vivo investigations are detailed for (R)-
6.
In Vitro Validation of the Anti-Inflammatory Bioactions of
Lead Compound (R)-6. (R)-6 Attenuates Inflammatory NF-κB
Activity in Smooth Muscle Cells (SMCs). vSMC-monocyte
cross-talk is a key driver of inflammation associated with
atherosclerosis.54 We evaluated the impact of (R)-6 on TNF-α-
stimulated NF-κB in cultured mouse primary vSMCs, as
previously described,18 by transfecting SMCs with an NF-κB
reporter plasmid (pNF-κB-SEAP vector) for 24 h and
subsequently stimulating SMCs with TNF-α (1 ng/mL) for
24 h in the presence or absence of a vehicle or (R)-6 (1 nM).We
observed a 5-fold increase inNF-κB activity in SMCs in response
to TNF-α, which was significantly (p < 0.05) reduced to 3-fold
by pretreating the TNF-α-challenged cells with the sLXms (R)-6
(Figure 7). As previously reported,18 LXA4 1 (0.1 nM) and 2 (1
nM) reduced TNF-α-stimulated NF-κB activity in this system.
(R)-6 Enhances Macrophage Phagocytosis. We measured
the effects of LXs and sLXms on phagocytosis of fluorescent
Escherichia coli bioparticles by cultured macrophages.55 As
anticipated from our previous work,56 LXA4 induced phagocytic
activity in macrophages but not in monocytes (data not shown).
Macrophages were pretreated for 30 min with increasing
concentrations (1 fM−1 μM) of LXA4 (1) and sLXms [(5) and
(R)-6]. LXA4 (1) significantly (p < 0.01) increased phagocytosis
by 4-fold in a concentration-dependent way, reaching a peak at
100 nM and going back to the baseline at 1 μM(Emax = 4.2± 2%;
EC50 = 5 nM). Overall, by looking at the shape of the curves, the
peak of LXA4 is right-shifted (low potency), while the peak of
sLXms falls right in the middle of the concentration−response
curve, resulting in similar efficiency but being more potent
(respectively, by 500× and 100×) (positive relative PD scores)
than the native compound. This result suggests an anti-
inflammatory activity preserving host defense for both sLXms
current leads [(5) and (R)-6] by enhancing the phagocytic
ability of MF0 macrophages, likely initiating a transition toward
an MF2 phenotype (Figure 8).
In Vivo Validation of the Anti-Inflammatory Bioactions of
Lead Compound (R)-6. With distinct anti-inflammatory
responses determined for LXA4 and sLXms in vitro (cytokine
release and NF-κB activation), we next evaluated the lead
compound in two in vivomodels of acute murine inflammation:
zymosan-induced peritonitis and carrageenan-induced paw
edema.
(R)-6 Displays Anti-Inflammatory Activity by Attenuating
Murine Zymosan-Induced Peritonitis. Treatment of mice (1
mg/200 μL H2O/mouse-zymosan injected ip = 40 mg/kg) was
associated with a massive influx of neutrophils into the
peritoneal cavity. Pretreatment of the animals with Dex (11
mg/kg, 200 μL ip 1 h prior to zymosan injection) significantly (p
< 0.01) reduced neutrophil influx by 33.5% of the maximal
response. Pretreatment with 6 μg/kg (R)-6 significantly (p <
0.05) reduced PMNs by 22.5% of themaximal response (relative
to vehicle + zymosan). Mean values of PMN counts were as
follows: 4.7 ± 0.5 × 106/mL (vehicle pretreatment and
zymosan); 4.4 ± 1.1 × 106/mL (low dose (R)-6 pretreatment
and zymosan); 3.2 ± 0.7 × 106/mL (high dose (R)-6
pretreatment and zymosan); and 2.4 ± 0.7 × 106/mL (Dex
and zymosan) (Figure 9). It is important to note that sLXms
were administered using the same regimen as Dex but with a
much lower dosage. Due to the fact that 70% of all leukocytes
measured were PMNs, a strongly similar trend was observed
when the effect of sLXms on the entire myeloid population (data
not shown) or on the PMN fraction was analyzed (Figure 9).
Furthermore, cells were specifically stained for PMNs (Ly6G-
Pacific Blue) or total macrophages (F4/80-AF488). Total
leukocytes were stained with CD11b-APC. Using appropriate
isotype controls, quadrants were drawn and data were plotted on
logarithmic-scale density- or dot-plots to investigate the relative
% of PMNs and monocytes/macrophages by flow cytometry.
The relative proportion of each cell type was found not to be
Figure 7. Effect of (R)-6 on TNF-α-induced NF-κB-driven luciferase
activity in vSMCs. Mouse primary vSMCs transfected with an NF-κB
reporter plasmid (pNF-κB-SEAP vector) were pretreated for 30 min
with sLXm (R)-6 (1 nM), vehicle, or appropriate controls. After 24 h
from subsequent stimulation with TNF-α (1 ng/mL), supernatants
were collected and NF-κB-driven luciferase was assayed. Data are
expressed as fold change relative to vehicle± SEM (n = 6−8). Statistical
analyses using Student’s unpaired two-tailed t-test of the tested
compound vs TNF-α (**p < 0.01; ****p < 0.0001).
Figure 8. Effects of (R)-6 on E. coli-derived bioparticle phagocytosis by
THP-1-MF0 macrophage. A total of 1 × 105 THP-1-MF0 macrophage
were pretreated for 30 min with sLXms or appropriate controls (1 fM−
1 μM), following incubation (for 2 h at 37 °C) with fluorescently
labeled E. coli-derived bioparticles, prior to measuring the fluorescent
signal indicating the uptake of the bioparticles by the macrophages.
Data are expressed as fold change ± SEM (n = 3). Concentration−
response curves show the Emax (black circles) and EC50 (white circles).
Statistical analyses were carried out using Student’s unpaired two-tailed
t-test of the tested compound vs vehicle-treated (veh) (not shown).
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altered by treatment with either Dex or sLXms (data not
shown).
(R)-6 Reduced Acute Inflammatory Response to Carra-
geenan Paw Swelling. In a murine model, carrageenan
injection (1%) induced a self-limiting inflammatory response
(paw swelling) that resolved after 72 h. The peak of
inflammation was observed at 24 h as previously described.57
Inflammation was markedly attenuated in animals treated with
(R)-6 (2 μg/kg, ip): the peak response observed was
significantly reduced (p < 0.05) relative to that seen in
vehicle-treated animals (Figure 10). Interestingly, the time
taken to reduce the inflammatory response to 50% max is
Figure 9. Effect of sLXm (R)-6 onmurine zymosan-induced peritonitis. Mice were pretreated with (R)-6 (2 μg/kg and 6 μg/kg) or Dex (1 mg/kg) by
ip injection 30 min prior to zymosan (40 mg/kg) administration and again 1 h after zymosan injection. Peritoneal cells were collected by lavage 24 h
after zymosan injection. (a) Graphs and dot-plots show PMN counts corresponding to Ly6G+ cells. Surface marker expression on peritoneal cells was
assessed by flow cytometry. One-way analysis of variance (ANOVA) statistical analysis was performed, *p < 0.05. (b) Table displays the absolute count
and relative % of maximal response. Data are presented as mean ± SEM, n = 5 mice/treatment group.
Figure 10. Effect of sLXm (R)-6 onmurine carrageenan-induced paw edema. (R)-6, (R)-17 (2 μg/kg), or Naproxen (50mg/kg, po) was administered
30 min before the intrapaw injection of 1% carrageenan into male C57bl/6 mice. Paw swelling was monitored over time using an external lever gauge.
(a) Graph shows the paw edema index. One-way ANOVA statistical analysis was performed, *p < 0.05, **p < 0.01, ***p < 0.001. (b) Table displays
the index of each tested molecule relative to the carrageenan-induced levels. Data are presented as mean ± SEM, n = 3 mice/treatment group.
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reduced in (R)-6-treated animals by 6 h relative to that in
vehicle-treated animals. This interval is designated in Figure 10
as ΔΤR50. Consistently, (R)-17, a compound without effect on
inflammatory responses in vitro (Figure S2), had no effect on the
inflammatory response in this model. The conventional NSAID
Naproxen (50 mg/kg, po) was included in these studies for
comparison. The efficacy of (R)-6 (2 μg/kg) was comparable to
that of Naproxen regarding reduction of the peak of
inflammation (Figure 10). The difference in potency between
(R)-6 and Naproxen is noteworthy: 2 μg/kg vs 50 mg/kg,
respectively. In Naproxen-treated animals, inflammation
persisted after 72 h, the interval at which spontaneous resolution
was observed (Figure 10).
QNX-sLXm (R)-6 Is an ALX/FPR2 Receptor Agonist. ALX/
FPR2 is a G-protein-coupled receptor that is activated by the
endogenous ligands, including LXA4.
58 The molecular target of
sLXms was investigated using a cell line stably expressing the
ALX/FPR2 receptor coupled to a Gαq subunit.
59 ALX/FPR2
activation is coupled to Ca2+ release in this experimental system.
Using HEK-293 cells stably expressing the ALX/FPR2 receptor
together with a Gαq subunit,
60 receptor activation was
determined by transient Ca2+ flux. The control used was wild-
typeHEK cells to verify the specificity of the agonism toward the
ALX/FPR2 receptor, as previously described36 (Figure S6).
Treatment of cells with 100 nM LXA4 1 or (R)-6 (10 pM−100
nM) resulted in increased intracellular Ca2+, although, through a
direct comparison of LXA4 1 and (R)-6 at the same
concentration (10 pM), where they both maximally activate
ALX/FPR2, it is evident that activation by the mimetic was
significantly (p < 0.05) 40% lower than that induced by the
native LXA4 (a full agonist) (Figure 11). These data suggest that
the mimetic acts as a partial agonist of ALX/FPR2. The partial
agonism is also evidenced by the negative PD score relative to
the native compound 1 (Table S7). Moreover, in line with
observations from LXA4 (1) and the imidazolo-mimetic (5), at
10 pM and 1 nM, (R)-6 induced a similar activation, which was
significantly (p < 0.01) stronger than that observed at 100 nM.
These findings suggest that at higher doses (>100 nM) the
interaction with the receptor may reach saturation, probably due
to desensitization and/or internalization. These experiments
used ATP and W-peptide (Wp) as positive controls. ATP-
induced activation of Ca2+ mobilization is independent of ALX/
FPR2 (mediated via the GPCR purinergic receptor P2Y
endogenously expressed on HEK-293 cells).61 Ca2+ mobiliza-
tion was observed in ALX/FPR2 expressing cells as a result of
stimulation with ATP (1 μM) or Wp (2 nM). Importantly, ATP
stimulated Ca2+ mobilization in wild-type HEK-293 cells,
whereas the ALX/FPR2 ligands (sLXms, Wp, LXA4) were
without effect (Figure S6). In summary, our data show that (R)-
6 is a “partial agonist” at ALX/FPR2.
■ DISCUSSION
The well-established metabolic inactivation of LXA4 1,
31 along
with the expense and complexity of its synthesis, significantly
limits its potential as a therapeutic agent despite reports of its
benefits for the treatment of both acute2 and chronic
inflammation.4 Using the native LXA4 structure for inspiration,
we previously prepared and evaluated the anti-inflammatory
activities of a number of benzo-,34 pyridino-,35 and imidazolo-
mimetic36 LXA4 analogues. Now, we describe the asymmetric
synthesis of a focused library of quinoxalino-QNX-sLXms (6−
8). The successful synthetic route employed set up the required
stereochemistry through a combination of chiral pool (2-deoxy-
D-ribose) and asymmetric synthesis (ketone hydrogenation).
The Suzuki coupling reaction was used for the formation of the
heterocycle to the alkene bond and offers an alternative
approach to the one using the Heck reaction to prepare other
heteroaromatic-containing lipoxins.
The above-detailed synthetic strategy successfully led to eight
novel QNX-sLXms, which were screened in vitro for their
biological activity and safety profile. The anti-inflammatory
activity was evaluated by measuring their ability to regulate LPS-
induced inflammation in THP-1 Lucia monocytes and
subsequent cytokine release. Native LXA4 (1), a previously
reported LXA4 analogue [benzo-LXA4 (2)],
34 the current sLXm
lead compound (imidazolo-LXA4 5),
36 and dexamethasone62
were used as controls.
Briefly, the in vitro screening of the novel analogues
demonstrated that all tested sLXms, except for the QNX-
precursor acetonides (17), displayed a similar or more active
profile than native LXA4 (1) (Imax = 24 ± 1%; IC50 = 60 pM; rel.
slope = 1; PD score = ref) in attenuating LPS-induced NF-κB
Figure 11. Effects of (R)-6 on intracellular calcium flux in stably transfectedHEK-293. Cells were cultured for 18 h prior to labeling with Fluo-4 (37 °C,
1 h). (a) Quantification of three independent experiments was carried out by calculating differential calcium signals measured at the baseline and at
maximum peak. Data are expressed as % delta calcium-induced fluorescent signal relative to the peak of a known full agonist (1) ± SEM (n = 3).
Concentration−response curves for LXA4 (1) and sLXms (10 pM to 100 nM) show the Emax (black circles) and predicted EC50 (white dotted circles).
Statistical analyses were carried out using Student’s unpaired t-test of the tested compound vs veh (not shown).
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activity. Therefore, the acetonides (17) were excluded from
further characterization. Among the six remaining QNX-sLXms
tested, the quinoxaline analogue containing an alkyl chain of the
same length as 1 (6C chain) was shown to be approximately
twice as effective as 1, thus conferring (R)-6 with a general PD
score of “+5” relative to the native compound. The SAR analysis
demonstrated that increasing the length of the alkyl chain by 2
carbons (thus obtaining an 8C chain) did not improve efficacy,
but slightly increased potency, compared to 1 (Imax = 23 ± 8%;
IC50 = 10−40 pM; rel. slope = 0.5). Reducing the length of the
alkyl chain by two carbons (thus obtaining a 4C chain) not only
reduced the potency but also ameliorated the efficacy (Imax =
29−36± 8%; IC50 = 1−4 nM; rel. slope = 0.6) (Figure 3, Figure
S2, and Table S2).
Furthermore, several of the analogues attenuated proin-
flammatory cytokine release. In particular, (R)-6 demonstrated
an immunomodulatory phenotype very similar to LXA4 (1) by
dramatically reducing the levels of IL-1b, IL-6, and IFN-γ
(Figure 3) and by enhancing IL-8 secretion, as clearly depicted
in Figure S3.
Notably, (1) and (R)-6were equally efficient but more potent
than Dex in enhancing LPS-induced release of IL-8 by 2.5-fold
(Figure S3). IL-8 has long been recognized to have both pro-
and anti-inflammatory activities, which has been established in
various models of infection, inflammation, and cancer.63 IL-8 is
known to inhibit leukocyte adhesion to activated endothelial
cells and thus exhibits anti-inflammatory properties. Interest-
ingly, IL-8 possessing 72 amino acids is ca. 10-fold more potent
in inhibiting neutrophil adhesion than the corresponding IL-8
variant containing 77 amino acids.64 It has been shown that
tissue-specific variations in endothelial chemokine secretion
rather than variations in adhesion molecules can explain the
different patterns of inflammation and leukocyte traffic seen in
nonlymphoid tissues.64 These data lead us to propose that, in a
similar manner to what happens in the endothelium, different
monocyte subtypes release different IL-8 isoforms. In this way,
LXs and sLXms may differentially induce a monocyte switch,
triggering the release of themore potent isoform that inhibits the
adhesion of neutrophils: the IL-872. Further studies will address
this hypothesis.
Overall, by comparing the effect of the three main compounds
tested [native compound, LXA4 (1), and the two sLXm leads,
(R)-6 and (5)] on cytokine release, it is evident that all reduce
NF-κB activity (Figures 3 and S2). However, their downstream
effect is a “fine tuning” of cytokine release through a series of
intermediate states, ranging between the abolishment of IL-6
and the enhancement of IL-8 (Figure S3). Such diverse actions
can be partially explained by the fact that certain cytokines are
simultaneously regulated by multiple transcription factors.
Therefore, the inhibitory effect exerted on NF-κB is not
sufficient to explain the pleiotropic responses observed, and it
is reasonable to suggest epigenetic regulation of cytokine
expression in response to SPMs.65
Evaluation of putative safety profiles by relating the biological
half-maximal activity to the intrinsic and extrinsic toxicities of
the compounds supported the conclusion that R-(6) displayed a
suitable safety profile for selection as the “lead compound”, thus
warranting validation in vitro and in vivo.
Given the importance of the cross-talk between monocytes
and vSMCs,54 the anti-inflammatory ability of R-(6) was also
confirmed in a different in vitro model: vSMCs stimulated with
TNF-α, thus mimicking a sterile inflammatory scenario in
contrast to LPS-evoked responses. The outcome confirmed the
ability of R-(6) to inhibit the NF-κB activity (Figure 7).
Having demonstrated the significant anti-inflammatory
properties of R-(6), it was relevant to test its effect on the
phagocytic ability of unprimed macrophages (MF0) derived
from THP-1 monocytes. It was revealed that sLXms-lead
compounds, 5 and (R)-6, displayed a similar efficacy to LXA4 in
enhancing E. coli bioparticles’ phagocytosis by MF0 macro-
phages (Figure 8), thus suggesting an anti-inflammatory action,
which preserves innate host defense against microbial invasion.
In vivo validation of the therapeutic potential of R-(6) was
investigated in two murine acute inflammatory models:
zymosan-induced peritonitis and carrageenan-induced paw
edema. The former showed a reduced neutrophil count in the
peritoneal lavage in response to (R)-6 administration,
suggesting a reduced infiltration of those immune cells in the
peritoneum (Figure 9). The latter model demonstrated an (R)-
6-mediated reduction in paw edema.
By comparing the kinetics of the lead compound with the
known endogenous and exogenous full agonists of ALX/FPR2
(Emax set to 100%), (R)-6 could be identified as equipotent
partial agonist at ALX/FPR2, having an Emax less than 100% but
displaying the same potency as the full agonists. This suggested
that QNX-sLXms, particularly (R)-6, induced a mild effect at
lower doses, which increased with higher concentrations, until it
reached a peak (Imax), after which the effect is reduced. These
findings suggest desensitization or internalization of the
receptor. This is in keeping with ALX/FPR2 internalization
that we previously reported in response to LXA4 at 1 nM.
14 This
is also supported by our calciummobilization analysis, where the
calcium peak is reached at the “pM range” for both LXA4 and
sLXms, which is consistent with the hypothesis of a
desensitization/internalization of ALX/FPR2 occurring at the
“nM range” (Figure 11). Since amolecule can activatemore than
one receptor (as is the case of epi-LXA4),
66 the specificity of the
interaction of (R)-6 with ALX/FPR2 was assessed in the wild-
type HEK-293 (which constitutively expresses low levels of the
receptor). In such a system, no calcium release was induced, thus
confirming the selectivity of the agonism of sLXm for ALX/
FPR2 (Figure S6). Therefore, (R)-6 was chosen as the lead
compound from this series and evaluated in further biological
assays.
Drug discovery routinely tests compounds for their activity
against a particular receptor using isolated tissues and high-
throughput assays. For compounds that behave as agonists, EC50
and Emax are the parameters normally measured, whereas
observed affinity and intrinsic efficacy are parameters of more
importance to drug development.
An important aspect of this study was the development of a
novel method for the analysis of an agonist’s concentration−
response curve so that the product of observed potency, efficacy,
and safety expressed relative to a standard agonist can be
estimated. This most comprehensive parameter, which we term
the “relative pharmacodynamic [PD] score”, implements and
complements pre-existing indices [i.e., the intrinsic relative
activity (RAi) by Griffin].67 It is readily applicable (1) for
analyzing responses at G-protein-coupled receptors; (2) for
detecting agonist-directed signaling: [upstream of the second
messenger level (i.e., calcium mobilization), middle stream (i.e.,
NF-κB activity), and downstream response (i.e., cytokine
release)]; and (3) for a more accurate in vitro screening tool,
being based on a more comprehensive index than pre-existing
ones. In fact, the PD score is equivalent to a “summative index”
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of the potency, efficacy, and slope of curve ratios that agonists
would be predicted to exhibit in an assay that is hypothetical and
highly sensitive in which all agonists act as full agonists, even
those that possess low levels of intrinsic efficacy.
Taken together, this novel pharmacodynamic approach
supports and confirms the novel inflammatory regulator
potential of heteroaromatic sLXms, as already demonstrated
by us for LXs56a and imidazole-sLXms.36
■ CONCLUSIONS
In this study, eight novel sLXm analogues were designed and
successfully prepared in an asymmetric synthesis mainly
consisting of a combination of chiral pool (2-deoxy-D-ribose)
and enantioselective ketone reduction. These eight candidate
molecules were biologically evaluated using an innovative
scoring system (PD score) based on three PD components
(potency, efficacy, slope). The PD study was conducted (1) to
analyze the upstream response at the GPCR ALX/FPR2 in
HEK-293 cells (by measuring the stimulation of calcium
mobilization through Gaq); and (2) to screen the candidate
molecules through a novel in vitro approach (by measuring the
NF-κB activity and the downstream release of proinflammatory
cytokines and LDH of monocytes as well as the phagocytic
activity of macrophages).
In summary, all tested QNX-sLXms were shown to have
minimal toxic effects on human monocytes and displayed a
similar or more active profile than the native LXA4 (1) in
attenuating LPS-induced NF-κB activity. Of the QNX-sLXms
tested, the quinoxaline analogue (R)-6 demonstrated a superior
PD profile than the native compound. The effect of (R)-6 was
especially noteworthy in the context of attenuation of cytokine
release. The SAR analysis demonstrated that increasing the alkyl
chain length led to a reduction in efficacy, while reducing the
alkyl chain length also negatively affected potency. Combining
the outcomes from subsequent in vivo validation models, a role
emerged for (R)-6 as an “immuno-modulator” of the neutrophil
count and edema formation.
These data clearly demonstrate the therapeutic potential of
QNX-sLXms as novel inflammatory regulators.
■ EXPERIMENTAL SECTION
General Information. Chemistry Materials and Methods.
General Experimental. Starting materials were supplied from
commercial sources and used without further purification. All
commercially available solvents were used as supplied unless otherwise
stated. Anhydrous diethyl ether (Et2O), tetrahydrofuran (THF), and
dichloromethane (CH2Cl2) were obtained from a Grubbs-type still,
supplied by the Innovative Technology Inc. Pure Solv-400-3-MD
solvent purification system. Oxygen-free nitrogen was obtained from
BOC gases and was used without further drying. Infrared spectroscopy
was performed on a Varian FT-IR 3100 spectrometer. 1H NMR spectra
were recorded on Varian-Inova spectrometers (300, 400, and 500
MHz) using tetramethylsilane as an internal standard. 13C NMR
spectra were recorded on 400 and 500 MHz Varian-Inova
spectrometers (101 and 125 MHz) using tetramethylsilane as an
internal standard. 19F NMR spectra were recorded on a 400 MHz
Varian-Inova spectrometer (376 MHz). CDCl3, purchased from
Aldrich, was used as supplied. High-resolution mass spectra (HRMS)
were obtained using a Micromass/Walters LCT instrument. Super-
critical fluid chromatography (SFC) was performed on a Waters
Acquity UPC2 instrument with Chiralpak IA3, IB3, IC3, and ID3
columns. High-performance liquid chromatography (HPLC)-grade
solvents, purchased from Aldrich, were used as supplied. TLC was
performed on Merck precoated Kieselgel 60 F254 aluminum plates with
realization by UV irradiation or by charring with acidic vanillin. Flash
column chromatography was performed on Davisil silica LC60A,
particle size 0.040−0.063 mm. Optical rotation measurements were
recorded using a Schmidt-Haensch Unipol L2000 polarimeter at 589
nm and are quoted in units of deg dm−1 cm3 g−1 (concentration c is
given in g/100 mL). Melting points were determined in open capillary
tubes with a Barnstead Electrothermal 9300 melting point apparatus.
All tested compounds have a purity > 95% as determined by HPLC.
Experimental Method. 1-(3-Chloro-quinoxalin-2-yl)-hexan-1-one
(11). 2-Chloroquinoxaline (500 mg, 3.04 mmol, 1 equiv) was dissolved
in EtOAc (23 mL). Hexanal (1.5 mL, 12.15 mmol, 4 equiv) and
TMSN3 (0.8 mL, 6.08 mmol, 2 equiv) were added. PhI(OCOCF3)2
(2.61 g, 6.08 mmol, 2 equiv) was added portionwise over 10 min, and
the mixture turned orange in color. The mixture was stirred at room
temperature for 2 h. Additional TMSN3 (0.8 mL, 6.08 mmol, 2 equiv)
and PhI(OCOCF3)2 (2.61 g, 6.08 mmol, 2 equiv) were added, and the
reaction mixture was stirred for a further 16 h. Triethylamine (7 mL)
was added dropwise, and the mixture was stirred for 15 min, filtered
through Celite, and washed with 10% CuSO4 solution (3 × 50 mL),
water (25 mL), and brine (25 mL). The organic layer was dried with
MgSO4, filtered, and concentrated. The crude mixture was purified by
silica gel column chromatography (50:1 → 20:1 pentane/EtOAc) to
afford product 11 as a yellow solid (572 mg, 72%). Rf = 0.4 (20:1
pentane/EtOAc); mp = 45−48 °C; 1H NMR (400 MHz, CDCl3) δ
8.12 (dd, J = 8.0, 1.5 Hz, 1H), 8.04 (dd, J = 8.0, 1.5 Hz, 1H), 7.85 (m,
2H), 3.18 (t, J = 7.5 Hz, 2H), 1.82−1.72 (m, 2H), 1.44−1.31 (m, 4H),
0.91 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 200.7, 148.2,
143.7, 142.3, 139.5, 132.6, 130.8, 129.54, 128.3, 40.4, 31.3, 23.2, 22.4,
13.9; IR (neat) (νmax, cm
−1) 3435, 1710, 1265; HRMS (ESI) [M +H]+
calcd 263.0951 for C14H16O
35Cl; found 263.0941.
1-(3-Chloroquinoxalin-2-yl)hexan-1-ol (14). Ketone 11 (97 mg,
0.369mmol, 1 equiv) was dissolved in dryMeOH (2mL) and cooled to
0 °C. NaBH4 (40 mg, 1.057 mmol, 2.9 equiv) was added. The reaction
was stirred at room temperature for 2 h and then was quenched by the
addition of acetone (5 mL). The solvent was removed in vacuo, and the
mixture was resuspended in a saturated aqNH4Cl solution (25mL) and
extracted with CH2Cl2 (3× 20mL). The organic layer was washed with
water (20 mL) and brine (20 mL), dried over MgSO4, filtered, and
concentrated. The crude product was purified by silica gel column
chromatography (10:1 pentane/EtOAc) to afford product 14 as a pale-
yellow solid (57 mg, 58%). Rf = 0.50 (pentane/EtOAc 6:1); mp = 73−
79 °C; 1H NMR (400 MHz, CDCl3) δ 8.12−8.06 (m, 1H), 8.06−8.00
(m, 1H), 7.88−7.72 (m, 2H), 5.17 (m, 1H), 4.05 (d, J = 8.0 Hz, 1H),
2.06−1.98 (m, 1H), 1.65−1.54 (m, 3H), 1.41−1.25 (m, 4H), 0.88 (t, J
= 7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 156.0, 145.4, 141.8,
139.9, 130.9, 130.7, 128.6, 128.4, 70.6, 37.2, 31.7, 25.4, 22.7, 14.2; IR
(CHCl3) (νmax, cm
−1) 3476, 2958, 1466, 1048; HRMS (ESI) [M +H]+
calcd 265.1108 for C14H18
35ClN2O; found 265.1106.
(S)-1-(3-Chloroquinoxalin-2-yl)hexan-1-ol ((1S)-14). Quinoxaline
ketone 11 (50 mg, 0.190 mmol, 1 equiv) was dissolved in iPrOH (2.5
mL). RuCl2[(R)-xylBinap][(R)-DAIPEN] (12 mg, 0.0095 mmol, 0.05
mmol), tBuOK (6 mg, 0.0535 mmol, 0.28 equiv), and triisopropyl
borate (0.01 mL) were added, and the reaction mixture was stirred
under 10 bar of H2 for 24 h. The mixture was concentrated and purified
by silica gel column chromatography (10:1 pentane/EtOAc), and
product (1S)-14was isolated as a pale-yellow solid (27 mg, 54%). Mp =
78−81 °C; [α]D =−7.22 (c = 1.5 in CHCl3); ee = 97% as determined by
SFC using a Chiralpak IC column (CO2/MeCN, gradient 99:1 0−1
min and then gradient to 60:40 until 5 min, 3 mL/min), Rt = 3.00 min
(S)-enantiomer, 3.41 min (R)-enantiomer. Identical in all other
physical data to the previously prepared racemic 14.
(R)-1-(3-Chloroquinoxalin-2-yl)hexan-1-ol ((1R)-14). Quinoxaline
ketone 11 (100 mg, 0.381 mmol, 1 equiv) was dissolved in iPrOH (3
mL). RuCl2[(S)-xylbinap][(S)-DAIPEN] (23 mg, 0.019 mmol, 0.05
mmol), tBuOK (11 mg, 0.095 mmol, 0.25 equiv), and triisopropyl
borate (0.02 mL) were added, and the reaction mixture was stirred
under 10 bar of H2 for 18 h. The mixture was concentrated and purified
by silica gel column chromatography (10:1 pentane/EtOAc), and
product (1R)-14was isolated as a pale-yellow solid (40mg, 40%).Mp =
78−81 °C; [α]D = +13.49 (c = 1.5 in CHCl3); ee = 98% as determined
by SFC using a Chiralpak IC column (CO2/MeCN, gradient 99:1 0−1
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min and then gradient to 60:40 until 5 min, 3 mL/min), Rt = 3.00 min
(S)-enantiomer, 3.41 min (R)-enantiomer. Identical in all other
physical data to the previously prepared racemic 14.
1-(3-Vinylquinoxalin-2-yl)hexan-1-ol (15). Pd(PPh3)4 (31 mg, 5
mol %) and LiCl (80 mg, 1.887 mmol, 4 equiv) were dissolved in dry
1,4-dioxane (2 mL). Aryl chloride 14 (121 mg, 0.457 mmol, 1 equiv),
dissolved in dioxane (3 mL), was added, followed by tributyl(vinyl)-
stannane (0.17 mL, 0.589 mmol, 1.3 equiv), and the reaction mixture
was heated to 80 °C, sealed under nitrogen, and stirred for 16 h. The
reaction mixture was allowed to cool, filtered through a pad of celite,
eluted with CH2Cl2 (20mL), and concentrated. The crude product was
purified by silica gel column chromatography (10:1 cyclohexane/
EtOAc) to afford product 15 as an orange oil (104 mg, 88%). Rf = 0.6
(6:1 pentane/EtOAc); 1H NMR (400 MHz, CDCl3) δ 8.11−8.04 (m,
1H), 8.04−7.99 (m, 1H), 7.76−7.67 (m, 2H), 7.04 (dd, J = 16.8, 10.7
Hz, 1H), 6.67 (dd, J = 16.8, 1.7 Hz, 1H), 5.75 (dd, J = 10.7, 1.7 Hz, 1H),
5.14 (td, J = 7.5, 3.0 Hz, 1H), 4.65 (d, J = 7.5 Hz, 1H), 1.87 (dt, J = 9.8,
7.0 Hz, 1H), 1.59−1.48 (m, 3H), 1.35−1.26 (m, 4H), 0.90 (t, J = 7.5
Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 155.1, 147.6, 141.8, 140.0,
130.5, 129.8, 129.7, 129.2, 128.2, 123.6, 69.9, 38.1, 31.6, 25.3, 22.6,




Grubbs II catalyst (22 mg, 0.035 mmol, 10 mol %) was added to a
Schlenk tube. Acetonide chain 16 (97 mg, 0.412 mmol, 1.15 equiv) and
vinyl quinoxaline 15 (95 mg, 0.358 mmol, 1 equiv) dissolved in dry
CH2Cl2 (1.1 mL) were added, and the reaction was heated to 39 °C and
stirred for 96 h. The reaction mixture was concentrated and purified by
silica gel column chromatography (6:1→ 1:1 pentane/EtOAc) to give
product 17 as a brown oil (41mg, 26%). Rf = 0.2 (6:1 pentane/EtOAc);
1H NMR (500 MHz, CDCl3) δ 8.11−8.05 (m, 1H), 8.02 (dd, J = 6.0,
2.0 Hz, 1H), 7.76−7.69 (m, 2H), 7.17 (dt, J = 15.0, 6.0 Hz, 1H), 7.02−
6.94 (m, 1H), 5.15 (d, J = 7.0 Hz, 1H), 4.86 (q, J = 7.0 Hz, 1H), 4.69−
4.62 (2 x d, J = 7.0 Hz, 1H), 4.32 (dt, J = 15.0, 4.5 Hz, 1H), 3.66 (s, 1H),
3.63 (d, J = 2.5 Hz, 2H), 2.40−2.32 (m, 2H), 1.92−1.69 (m, 4H), 1.59
(d, J = 2.0 Hz, 3H), 1.55 (dd, J = 8.0, 3.0 Hz, 2H), 1.44 (d, J = 3.0 Hz,
3H), 1.37−1.25 (m, 6H), 0.89 (dt, J = 12.0, 6.0 Hz, 3H); 13C NMR
spectrum complicated by a mixture of diastereomers (NMR spectra of
individual diastereomers are reported vide infra); IR (CHCl3) (νmax,
cm−1) 3054, 1733, 1422, 1266; HRMS (ESI) [M + H]+ calcd 457.2702
for C26H37N2O5; found, 457.2702.
(3aR,7aS)-2,2-Dimethyltetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-
6-ol (20).68 2-Deoxy-D-ribose (10.0 g, 74.6 mmol, 1 equiv) and
pyridinium 4-toluenesulfonate (500 mg, 1.99 mmol, 2.7 mol %) were
dissolved in acetone (125 mL). The reaction mixture was stirred for 15
min. 2-Methoxypropene (14.0 mL, 146.19 mmol, 2 equiv) was then
added, and the reaction was stirred at room temperature for 18 h. The
reaction mixture was filtered using a Buchner funnel, and triethylamine
(1.0 mL) was added to the filtrate. The mixture was concentrated, and
the crude product was purified by silica gel column chromatography
(4:1 → 1:1 pentane/EtOAc) to afford product 20 as a light-yellow oil
(7.65 g, 59%). Spectral data were consistent with the literature; Rf =
0.25 (1:1 pentane/EtOAc); 1H NMR (400 MHz, CDCl3) δ 5.25 (dd, J
= 7.0, 4.5 Hz, 0.7H), 5.06 (m, 0.3H), 4.47 (dt, J = 6.5, 4.0 Hz, 0.7H),
4.40 (dd, J = 10.5, 5.0 Hz, 0.3H), 4.19−4.13 (m, 1H), 3.96−3.91 (m,
1H), 3.73−3.66 (m, 1H), 3.23−3.09 (m, 1H), 2.23 (dt, J = 15.0, 4.5 Hz,
0.7H), 2.10−2.06 (m, 0.6H), 1.77 (ddd, J = 15.0, 7.0, 5.0 Hz, 0.7H),
1.53 (s, 1H), 1.49 (s, 2H), 1.35−1.32 (m, 3H); [α]D = −14.1 (c = 0.95
in CHCl3) (Lit. [α]D = −18.5 (c = 4.2 in CHCl3)).
Methyl (E)-4-((4S,5R)-5-(Hydroxymethyl)-2,2-dimethyl-1,3-dioxo-
lan-4-yl)but-2-enoate (21).68 Methyl (triphenylphosphoranylidene)-
acetate (8.81 g, 26.4 mmol, 1.2 equiv) was dissolved in THF (120 mL).
The protected ribose 20 (3.83 g, 21.958 mmol, 1 equiv), dissolved in
THF (30 mL), was added followed by benzoic acid (134 mg, 1.099
mmol, 5 mol %). The mixture was heated to reflux and stirred for 4 h.
The reaction was allowed to cool to room temperature, filtered through
a pad of celite, and then eluted with Et2O (80 mL), and the reaction
mixture was washed with a saturated aq NH4Cl solution (50 mL), H2O
(50 mL), and brine (50 mL). The organic phase was then dried over
MgSO4, filtered, and concentrated, and the crude mixture was purified
by silica gel column chromatography (4:1 → 3:1 pentane/EtOAc) to
afford product 21 as a yellow oil (3.958 g, 78%). Spectral data were
consistent with the literature;68 Rf = 0.30 (1:1 pentane/EtOAc);
1H
NMR (300MHz, CDCl3) δ 6.97 (dt, J = 15.5, 7.0 Hz, 1H), 5.93 (dt, J =
15.0, 1.5 Hz, 1H), 4.29 (ddd, J = 8.5, 6.0, 5.0 Hz, 1H), 4.20 (dd, J = 11.5,
5.5 Hz, 1H), 3.73 (s, 3H), 3.65 (t, J = 5.5 Hz, 2H), 2.60−2.37 (m, 2H),
1.47 (s, 3H), 1.36 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 166.8,
145.0, 123.3, 108.7, 77.6, 75.5, 61.6, 51.7, 32.6, 28.1, 25.4; IR (CH2Cl2)
(νmax, cm
−1) = 3053, 2987, 1725, 1712, 1265, 1217, 1069; [α]D =
−28.26 (c = 0.65 in CHCl3); HRMS (ESI) [M + Na]+ calcd 253.1052
for C11H18O5Na; found, 253.1057.
Methyl 4-((4R, 5S)-5-(Hydroxymethyl)-2, 2-dimethyl-1, 3-dioxo-
lan-4-yl) butanoate (22).68 Alkene 21 (2.469 g, 10.72 mmol, 1 equiv)
was dissolved in EtOAc (30 mL). The reaction flask was evacuated and
backfilled with N2 three times. Then, 10% Pd/C (250 mg, 10 wt %) was
added and the flask was evacuated and backfilled with N2. The flask was
then evacuated and backfilled with H2 three times and stirred under a
balloon of H2 at room temperature for 16 h. The reaction mixture was
filtered through a pad of celite, eluted with EtOAc, and concentrated to
afford the title compound 22 as a colorless oil (2.327 g, 95%). Rf = 0.32
(1:1 pentane/EtOAc); 1H NMR (300 MHz, CDCl3) δ 4.15 (m, 2H),
3.66 (s, 3H), 3.60 (d, J = 4.0Hz, 2H), 2.37 (td, J = 7.0, 4.5 Hz, 2H), 2.17
(s, 1H), 1.93−1.50 (m, 4H), 1.45 (s, 3H), 1.35 (s, 3H); 13C NMR (101
MHz, CDCl3) δ 173.8, 108.1, 77.8, 76.6, 61.6, 51.5, 33.6, 28.3, 28.1,
25.4, 22.0; IR (neat) (νmax, cm
−1) 3469, 2881, 1712, 1249, 1216, 1043;
[α]D = + 14.48 (c = 2.3 in CHCl3)
68 [α]D = +21.8 (c = 2.7 in CHCl3);
HRMS (ESI) [M + Na]+ calcd 255.1208 for C11H20O5Na; found,
255.1200.
Methyl 4-((4S,5S)-5-Formyl-2,2-dimethyl-1,3-dioxolan-4-yl)-
butanoate (23). Alcohol 22 (1.2 g, 5.17 mmol, 1 equiv) was dissolved
in CH2Cl2 (8 mL), and diacetoxyiodobenzene (2.00 g, 6.20 mmol, 1.2
equiv) and TEMPO (202 mg, 1.293 mmol, 0.25 equiv) were added.
The reaction was stirred at room temperature for 4 h, after which the
solvent, a crude mixture, was purified by silica gel column
chromatography (6:1→ 3:1 pentane/EtOAc). Product 23 was isolated
as a pale-yellow oil (930 mg, 82%). Rf = 0.53 (1:1 pentane/EtOAc);
1H
NMR (400 MHz, CDCl3) δ 9.63 (d, J = 3.0 Hz, 1H), 4.36−4.30 (m,
1H), 4.25 (dd, J = 7.0, 3.0 Hz, 1H), 3.66 (s, 3H), 2.35 (t, J = 7.0 Hz,
2H), 1.88−1.60 (m, 4H), 1.57 (s, 3H), 1.40 (s, 3H); 13C NMR (101
MHz, CDCl3) δ 202.1, 173.5, 110.6, 81.9, 78.2, 51.5, 33.5, 29.1, 27.6,
25.3, 21.9; IR (neat) (νmax, cm
−1) 3456, 1733, 1639, 1256, 909, 737;
[α]D = −14.5 (c = 0.94 in CHCl3); HRMS (ESI) [M + Na]+ calcd
253.1052 for C11H18O5Na; found, 253.1050.
Dichloromethyl Pinacol Boronate (24).40 CH2Cl2 (1.77 mL, 27.72
mmol, 1 equiv) was added to THF (45 mL) and cooled to −100 °C.
nBuLi (9.98 mL of 2.5 M sol., 24.95 mmol, 0.9 equiv) was added
dropwise over 45 min. The reaction mixture was stirred for a further 30
min at−100 °C. Trimethylborate (3.09 mL, 27.718mmol, 1 equiv) was
added in one portion, and the reaction mixture was stirred for 30 min.
HCl (5 mL of 5 M sol.) was added, and the reaction mixture was stirred
while warming to room temperature. The reaction mixture was diluted
with H2O (25mL), extracted with Et2O (3× 50mL), and concentrated
to a yellow oil. This was dissolved in toluene (50 mL), pinacol (3.275 g,
27.718, 1 equiv) was added, and the reaction mixture was refluxed for
72 h. The reaction mixture was concentrated and purified by vacuum
distillation, affording the purified product 24 as a colorless oil (3.7 g,
70%). Spectral data matched those previously reported;69 Bp = 94−96




CrCl2 (3.2 g, 26.06 mmol, 8 equiv) was dissolved in dry THF (20
mL) in a Schlenk tube. Aldehyde 23 (750 mg, 3.26 mmol, 1 equiv) and
boronic ester 24 (1.375 mg, 6.514 mmol, 2.0 equiv) were dissolved in
THF (8 mL) and added to the reaction flask. LiI (1.744 mg, 13.028
mmol, 4.0 equiv), dissolved in THF (5 mL), was added slowly. The
Schlenk tube was wrapped in a tin foil and stirred vigorously for 12 h
with the reaction mixture turning brown in color. The mixture was
poured onto ice-water (50 mL) and turned green in color. This was
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extracted with EtOAc (3 × 40 mL), and the extracts were washed with
brine (50 mL), dried over Na2SO4, filtered, and concentrated. The
crude product was purified by silica gel column chromatography (6:1
pentane: EtOAc→ 2:1 pentane/EtOAc) affording product 18 as a pale-
yellow oil (780 mg, 68%). Rf = 0.46 (6:1 pentane/EtOAc);
1H NMR
(500 MHz, CDCl3) δ 6.47 (dd, J = 18.0, 6.8 Hz, 1H), 5.69 (d, J = 18.0
Hz, 1H), 4.47 (td, J = 6.8, 1.0 Hz, 1H), 4.18−4.12 (m, 1H), 3.64 (s,
3H), 2.33 (td, J = 7.5, 1.5 Hz, 2H), 1.83−1.59 (m, 2H), 1.46 (s, 3H),
1.46−1.36 (m, 2H), 1.33 (s, 3H), 1.24 (s, 12H). 13C NMR (101 MHz,
CDCl3) δ 172.8, 147.0, 122.0, 107.5, 82.3, 79.4, 77.0, 50.5, 32.7, 28.8,
27.1, 24.6, 23.8, 23.7, 20.8; IR (CHCl3) (νmax, cm
−1) 3435, 3020, 1734,
1648, 1216; [α]D =−1.72 (c = 1.0 in CHCl3); HRMS (ESI) [M +Na]+
calcd 377.2111 for C18H31O6Na; found, 377.2108.
Methyl 4-((4S,5R)-5-((E)-2-(3-((R)-1-Hydroxyhexyl)quinoxalin-2-
yl)vinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)butanoate ((1R)-17).
Bis(benzonitrile)Pd(II)chloride (10 mg, 0.0261 mmol, 0.17 equiv)
and dppb (18 mg, 0.0422 mmol, 0.28 equiv) were dissolved in toluene
(1 mL) and stirred at room temperature for 30 min to give a creamy
orange solution. Quinoxaline alcohol (1R)-14 (40 mg, 0.151 mmol, 1
equiv), dissolved in toluene (1mL), and boronic ester 18 (62mg, 0.180
mmol, 1.2 equiv), dissolved in toluene (1 mL), were added followed by
EtOH (0.05 mL) and Na2CO3 (0.17 mL of a 1 M aq solution, 0.177
mmol, 1.2 equiv). The reaction mixture was heated to 110 °C and
stirred for 18 h, after which it was diluted with H2O (20 mL) and
extracted with EtOAc (3 × 15 mL), and the extracts were then washed
with brine (20 mL), dried with MgSO4, filtered, and concentrated. The
crude reaction mixture was purified by silica gel column chromatog-
raphy (10:1→ 2:1 pentane/EtOAc) to give product (1R)-17 as a pale-
yellow oil (33 mg, 48%). Rf = 0.2 (6:1 pentane/EtOAc);
1HNMR (400
MHz, CDCl3) δ 8.11−7.94 (m, 2H), 7.70 (m, 2H), 7.14 (dd, J = 15.0,
6.0Hz, 1H), 6.97 (d, J = 15.0Hz, 1H), 5.16−5.10 (m, 1H), 4.84 (dd, J =
11.0, 5.5Hz, 1H), 4.64 (d, J = 6.5Hz, 1H), 4.30 (dt, J = 8.5, 5.5Hz, 1H),
3.63 (s, 3H), 2.43−2.23 (m, 2H), 1.94−1.80 (m, 2H), 1.76−1.63 (m,
2H), 1.57 (s, 3H), 1.42 (s, 3H), 1.34−1.21 (m, 8H), 0.85 (t, J = 7 Hz,
3H). 13C NMR (101 MHz, CDCl3) δ 173.7, 155.1, 146.9, 141.8, 139.8,
135.9, 129.7, 129.7, 129.1, 128.2, 125.3, 108.7, 78.3, 78.3, 69.8, 51.5,
38.1, 33.7, 31.5, 30.1, 28.2, 25.6, 25.2, 22.6, 21.8, 14.0; IR (CHCl3)
(νmax, cm
−1) 3054, 1733, 1422, 1266; [α]D = +2.21 (c = 0.8 in CHCl3);




Bis(benzonitrile)Pd(II)chloride (10 mg, 0.0261 mmol, 0.17 equiv)
and dppb (18 mg, 0.0422 mmol, 0.28 equiv) were dissolved in toluene
(1 mL) and stirred at room temperature for 30 min to give a creamy
orange solution. Quinoxaline alcohol (1S)-14 (39 mg, 0.147 mmol, 1
equiv), dissolved in toluene (1mL), and boronic ester 18 (70mg, 0.198
mmol, 1.3 equiv), dissolved in toluene (1 mL), were added followed by
EtOH (0.05 mL) and Na2CO3 (0.17 mL of a 1 M aq solution, 0.177
mmol, 1.2 equiv). The reaction mixture was heated to 110 °C and
stirred for 14 h after which it was diluted with H2O (20 mL) and
extracted with EtOAc (3 × 20 mL), and the extracts were then washed
with brine (20 mL), dried with MgSO4, filtered, and concentrated to
give a crude mixture, which was purified by silica gel column
chromatography (10:1 → 2:1 pentane/EtOAc) to give product (1S)-
17 as a pale-yellow oil (27 mg, 40%). Rf = 0.2 (6:1 pentane/EtOAc);
1H
NMR (500 MHz, CDCl3) δ 8.04−7.92 (m, 2H), 7.70−7.61 (m, 2H),
7.10 (dd, J = 15.0, 6.0 Hz, 1H), 6.90 (d, J = 15.0 Hz, 1H), 5.08 (m, 1H),
4.80 (t, J = 6.0 Hz, 1H), 4.62 (d, J = 7.0 Hz, 1H), 4.25 (dd, J = 13.5, 6.0
Hz, 1H), 3.55 (s, 3H), 2.33−2.24 (m, 2H), 1.85−1.78 (m, 2H), 1.70−
1.63 (m, 1H), 1.53 (s, 3H), 1.51−1.47 (m, 4H), 1.37 (s, 3H), 1.33−
1.20 (m, 5H), 0.81 (t, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ
174.3, 155.3, 147.3, 141.9, 140.0, 137.9, 130.0, 129.9, 129.1, 128.5,
125.4, 75.2, 74.1, 70.1, 51.8, 38.1, 33.8, 31.8, 31.5, 25.3, 22.7, 21.2, 14.2;
IR (CHCl3) (νmax, cm
−1) 3054, 1733, 1422, 1266; [α]D = +83.31 (c =
0.85 in CHCl3); HRMS (ESI) [M + H]
+ calcd 457.2702 for
C26H37N2O5; found, 457.2706.
Methyl (5S,6R,E)-5,6-Dihydroxy-8-(3-((S)-1-hydroxyhexyl)-
quinoxalin-2-yl)oct-7-enoate ((1S)-6). Acetonide (1S)-17 (20 mg,
0.0438 mmol, 1 equiv) was dissolved in MeOH (0.5 mL),
camphorsulfonic acid (9 mg, 0.0387 mmol, 0.88 equiv) was added,
and the reaction mixture was stirred at room temperature for 3 h. The
mixture was diluted with Et2O (20mL), washed withH2O (20mL) and
brine (20 mL), and the organic layer was dried with MgSO4, filtered,
and concentrated. The crude product was purified by preparative thin-
layer chromatography (96:4 CH2Cl2/MeOH). Product (1S)-6 was
isolated as a yellow oil (15 mg, 83%). Rf = 0.36 (96:4 CH2Cl2/MeOH);
1H NMR (500 MHz, CDCl3) δ 8.07−7.99 (m, 2H), 7.74−7.69 (m,
2H), 7.22 (dd, J = 15.0, 5.5 Hz, 1H), 7.04 (dd, J = 15.0, 1.5 Hz, 1H),
5.16 (dd, J = 7.5, 3.0 Hz, 1H), 4.51−4.47 (m, 1H), 3.85 (dt, J = 8.5, 4.0
Hz, 1H), 3.66 (s, 3H), 2.37 (td, J = 7.0, 2.0 Hz, 2H), 1.93−1.85 (m,
2H), 1.79−1.72 (m, 1H), 1.62−1.53 (m, 4H), 1.35−1.24 (m, 6H), 0.87
(t, J = 7.0 Hz, 3H); 13CNMR (101MHz, CDCl3) δ 174.4, 155.3, 147.3,
141.8, 140.0, 137.9, 130.0, 129.9, 129.1, 128.5, 125.3, 75.2, 74.1, 70.2,
51.8, 38.1, 33.8, 31.8, 31.4, 25.3, 22.7, 21.2, 14.2; IR (CHCl3) (νmax,
cm−1) 3434, 3054, 1734, 1422, 1265; [α]D = −14.33 (c = 0.75 in
CHCl3); HRMS (ESI) [M + Na]
+ calcd 439.2209 for C23H32O5Na;
found, 439.2213.
Methyl (5S,6R,E)-5,6-Dihydroxy-8-(3-((R)-1-hydroxyhexyl)-
quinoxalin-2-yl)oct-7-enoate ((1R)-6). Acetonide (1R)-17 (25 mg,
0.055 mmol, 1 equiv) was dissolved in MeOH (1.5 mL),
camphorsulfonic acid (14 mg, 0.060 mmol, 1.1 equiv) was added,
and the reaction mixture was stirred at room temperature for 3 h. The
mixture was concentrated and purified by preparative thin-layer
chromatography (96:4 CH2Cl2/MeOH). Product (1R)-6 was isolated
as a yellow oil (15 mg, 65%). Rf = 0.36 (96:4 CH2Cl2/MeOH);
1H
NMR (400 MHz, CDCl3) δ 8.07−7.95 (m, 2H), 7.75−7.67 (m, 2H),
7.25−7.19 (dd, J =15.0, 6 Hz, 1H), 7.01 (dd, J = 15.0, 1.5 Hz, 1H),
5.18−5.10 (m, 1H), 4.64 (d, J = 7.0 Hz, 1H), 4.49−4.44 (m, 1H),
3.89−3.82 (m, 1H), 3.66 (s, 3H), 2.75 (s, 1H), 2.63 (s, 1H), 2.38 (t, J =
7.5 Hz, 2H), 1.95−1.81 (m, 2H), 1.81−1.67 (m, 2H), 1.64−1.51 (m,
4H), 1.33−1.25 (m, 4H), 0.86 (t, J = 7.0Hz, 3H); 13CNMR (101MHz,
CDCl3) δ 174.2, 155.1, 147.1, 141.6, 139.9, 137.7, 129.8, 129.7, 128.9,
128.3, 125.3, 75.1, 74.0, 69.9, 51.6, 37.9, 33.6, 31.6, 31.5, 25.1, 22.6,
21.1, 14.0; IR (CHCl3) (νmax, cm
−1) 3434, 3054, 1734, 1422, 1265;
[α]D = +36.74 (c = 0.7 in CHCl3); HRMS (ESI) [M]
+ calcd 417.2389
for C23H32O5; found, 417.2371.
1-(3-Chloroquinoxalin-2-yl)butan-1-one (27). 2-Chloroquinoxa-
line (300 mg, 1.82 mmol, 1 equiv) was dissolved in EtOAc (14 mL).
Butyraldehyde (0.66 mL, 7.29 mmol, 4 equiv) and TMSN3 (0.48 mL,
3.65mmol, 2 equiv) were added. PhI(OCOCF3)2 (1.57 g, 3.65mmol, 2
equiv) was added portionwise over 15 min, and the mixture turned
orange in color. The mixture was stirred at room temperature for 2 h.
Further, TMSN3 (0.48 mL, 3.65 mmol, 2 equiv) and PhI(OCOCF3)2
(1.57 g, 3.65 mmol, 2 equiv) were added, and the reaction was stirred
for 16 h. Triethylamine (2 mL) was added dropwise, and the mixture
was stirred for 10 min. The reaction mixture was concentrated, and the
crude mixture was purified by silica gel column chromatography (50:1
cyclohexane/EtOAc) to afford product 27 as a yellow solid (234 mg,
57%). Rf = 0.42 (10:1 cyclohexane/EtOAc); mp = 33−36 °C; 1HNMR
(400MHz, CDCl3) δ 8.18−8.11 (m, 1H), 8.09−8.03 (m, 1H), 7.86 (m,
2H), 3.19 (t, J = 7.0 Hz, 2H), 1.87−1.78 (m, 2H), 1.06 (t, J = 7.5 Hz,
3H); 13C NMR (101 MHz, CDCl3) δ 200.6, 148.5, 143.7, 142.3, 139.5,
132.6, 130.8, 129.6, 128.3, 42.3, 17.1, 13.7; IR (CHCl3) (νmax, cm
−1)




ketone 27 (107 mg, 0.439 mmol, 1 equiv) was dissolved in iPrOH (2.5
mL). RuCl2[(S)-xylBinap][(S)-DAIPEN] (26 mg, 0.0212 mmol, 0.048
mmol), tBuOK (12 mg, 0.107 mmol, 0.24 equiv), and triisopropyl
borate (0.02 mL) were added, and the reaction mixture was stirred
under 25 bar of H2 for 18 h. The mixture was concentrated and purified
by silica gel column chromatography (20:1 → 10:1 cyclohexane/
EtOAc), and product (1R)-29 was isolated as a pale-yellow solid (75
mg, 69%).Rf = 0.31 (20:1 cyclohexane/EtOAc); mp = 100−104 °C; 1H
NMR (400 MHz, CDCl3) δ 8.09−8.04 (m, 1H), 8.04−7.99 (m, 1H),
7.79−7.73 (m, 2H), 5.19 (td, J = 8.0, 3.0 Hz, 1H), 4.10 (d, J = 8.0, 1H),
2.04−1.94 (m, 1H), 1.65−1.54 (m, 3H), 0.98 (t, J = 7.0 Hz, 3H); 13C
NMR (101 MHz, CDCl3) δ 155.9, 145.3, 141.7, 139.8, 130.8, 130.6,
128.5, 128.4, 70.3, 39.2, 18.9, 13.9; IR (CHCl3) (νmax, cm
−1) 3449,
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3020, 1641, 1050; [α]D = −41.16 (c = 2.0 in CHCl3); ee = 98% as
determined by SFC using a Chiralpak IC column (CO2/MeCN,
gradient 99:1 0−1 min and then gradient to 60:40 until 5 min, 3 mL/
min), Rt = 3.02 min (S)-enantiomer, 3.45 min (R)-enantiomer.
(S)-1-(3-Bromoquinoxalin-2-yl)butan-1-ol ((1S)-29). Quinoxaline
ketone 27 (107 mg, 0.439 mmol, 1 equiv) was dissolved in iPrOH (2.5
mL). RuCl2[(R)-xylBinap][(R)-DAIPEN] (26 mg, 0.0212 mmol,
0.048mmol), tBuOK (12mg, 0.107 mmol, 0.24 equiv), and triisopropyl
borate (0.02 mL) were added, and the reaction mixture was stirred
under 25 bar of H2 for 18 h. The mixture was concentrated and purified
by silica gel column chromatography (20:1 → 10:1 cyclohexane/
EtOAc), and product (1S)-29 was isolated as a pale-yellow solid (75
mg, 69%). [α]D = −41.16 (c = 2 in CHCl3); ee = 98% as determined by
SFC using a Chiralpak IC column (CO2:MeCN, gradient 99:1 0−1min
and then gradient to 60:40 until 5 min, 3 mL/min), Rt = 3.02 min (S)-
enantiomer, 3.45 min (R)-enantiomer; identical in all other physical
data to the previously prepared (1R)-enantiomer.
Methyl 4-((4S,5R)-5-((E)-2-(3-((R)-1-Hydroxybutyl)quinoxalin-2-
yl)vinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)butanoate ((1R)-31).
Bis(benzonitrile)Pd(II)chloride (18 mg, 0.048 mmol, 0.15 equiv)
and dppb (34mg, 0.079mmol, 0.25 equiv) were dissolved in toluene (1
mL) and stirred at room temperature for 30min to give a creamy orange
solution. Quinoxaline alcohol (1R)-29 (75 mg, 0.317 mmol, 1 equiv),
dissolved in toluene (1 mL), and boronic ester 18 (130 mg, 0.367
mmol, 1.16 equiv), dissolved in toluene (1 mL), were added followed
by EtOH (0.09 mL) and Na2CO3 (0.37 mL of a 1 M aq solution, 0.37
mmol, 1.15 equiv). The reaction mixture was heated to 110 °C and
stirred for 64 h. It was diluted with H2O (10 mL) and extracted with
EtOAc (3 × 10 mL), and the extracts were washed with brine (15 mL),
dried with MgSO4, filtered, and concentrated. The crude product was
purified by silica gel column chromatography (10:1 → 3:1 cyclo-
hexane/EtOAc) to give product (1R)-31 as a pale-yellow oil (36 mg,
27%). Rf = 0.15 (6:1 pentane/EtOAc);
1H NMR (400 MHz, CDCl3) δ
8.09−7.99 (m, 2H), 7.75−7.68 (m, 2H), 7.16 (dd, J = 15.0, 6.0 Hz,
1H), 6.99 (d, J = 15.0 Hz, 1H), 5.16 (td, J = 7.0, 3.0 Hz, 1H), 4.85 (t, J =
6.0Hz, 1H), 4.62 (d, J = 7.0Hz, 1H), 4.32 (dt, J = 8.5, 6.0 Hz, 1H), 3.63
(s, 3H), 2.39−2.32 (m, 2H), 1.91−1.72 (m, 3H), 1.62−1.50 (m, 8H),
1.44 (s, 3H), 0.98 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ
173.9, 155.3, 147.0, 142.0, 140.1, 136.1, 129.9, 129.8, 129.3, 128.4,
125.5, 108.9, 78.5, 78.5, 69.7, 51.7, 40.4, 33.8, 30.3, 28.4, 25.8, 22.0,
18.9, 14.0; IR (CHCl3) (νmax, cm
−1) 3316, 2960, 1729, 1650, 1216;
[α]D = +12.14 (c = 1.0 in CHCl3); HRMS (ESI) [M + H]
+ calcd
429.2389 for C24H33N2O5; found 429.2396.
Methyl 4-((4S,5R)-5-((E)-2-(3-((S)-1-Hydroxybutyl)quinoxalin-2-
yl)vinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)butanoate ((1S)-31).
Bis(benzonitrile)Pd(II)chloride (15 mg, 0.038 mmol, 0.15 equiv)
and dppb (27mg, 0.063mmol, 0.25 equiv) were dissolved in toluene (1
mL) and stirred at room temperature for 30min to give a creamy orange
solution. Quinoxaline alcohol (1S)-29 (60 mg, 0.253 mmol, 1 equiv),
dissolved in toluene (1 mL), and boronic ester 18 (113 mg, 0.319
mmol, 1.26 equiv), dissolved in toluene (1 mL), were added followed
by EtOH (0.08 mL) and Na2CO3 (0.29 mL of a 1 M aq solution, 0.29
mmol, 1.15 equiv). The reaction mixture was heated to 110 °C and
stirred for 48 h. The reaction mixture was diluted with H2O (10 mL)
and extracted with EtOAc (3 × 10 mL), and the extracts were washed
with brine (15 mL), dried with MgSO4, filtered, and concentrated. The
crude product was purified by silica gel column chromatography (6:1→
3:1 cyclohexane/EtOAc) to give product (1S)-31 as a pale-yellow oil
(30 mg, 28%). Rf = 0.15 (6:1 pentane/EtOAc);
1H NMR (400 MHz,
CDCl3) δ 8.10−7.98 (m, 2H), 7.77−7.67 (m, 2H), 7.17 (dd, J = 15.0,
5.5 Hz, 1H), 6.98 (dd, J = 15.0, 1.5 Hz, 1H), 5.21−5.13 (m, 1H), 4.86
(td, J = 6.5, 1.0 Hz, 1H), 4.69 (d, J = 7.0 Hz, 1H), 4.32 (ddd, J = 8.5, 6.5,
5.5 Hz, 1H), 3.62 (s, 3H), 2.40−2.31 (m, 2H), 1.92−1.81 (m, 2H),
1.78−1.68 (m, 1H), 1.59 (s, 3H), 1.59−1.50 (m, 5H), 1.44 (s, 3H),
0.96 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 173.7, 155.1,
146.9, 141.8, 139.8, 135.7, 129.7, 129.7, 129.1, 128.2, 125.1, 108.7, 78.3,
78.3, 69.6, 51.5, 40.3, 33.7, 30.2, 28.1, 25.6, 21.8, 18.9, 13.9; IR (CHCl3)
(νmax, cm
−1) 3316, 2960, 1729, 1650, 1216; [α]D = −94.53 (c = 1.5 in
CHCl3); HRMS (ESI) [M + H]
+ calcd 429.2389 for C24H33N2O5;
found, 429.2392.
Methyl (5S,6R,E)-5,6-Dihydroxy-8-(3-((R)-1-hydroxybutyl)-
quinoxalin-2-yl)oct-7-enoate ((1R)-7). Acetonide (1R)-31 (29 mg,
0.068 mmol, 1 equiv) was dissolved in MeOH (1.5 mL),
camphorsulfonic acid (16 mg, 0.068 mmol, 1 equiv) was added, and
the reaction mixture was stirred at room temperature for 3 h. The
mixture was diluted with Et2O (15 mL) and washed with H2O (10 mL)
and brine (10 mL), and the organic layer was dried with MgSO4,
filtered, and concentrated. The crude product was purified by
preparative thin-layer chromatography (96:4 CH2Cl2/MeOH). Prod-
uct (1R)-7 was isolated as a yellow oil (12 mg, 46%). Rf = 0.41 (96:4
CH2Cl2/MeOH);
1H NMR (400 MHz, CDCl3) δ 8.05−7.93 (m, 2H),
7.72−7.65 (m, 2H), 7.22 (dd, J = 15.0, 5.5 Hz, 1H), 7.01 (dd, J = 15.0,
1.5 Hz, 1H), 5.14 (dd, J = 7.5, 6.5 Hz, 1H), 4.65 (d, J = 6.5 Hz, 1H),
4.49−4.42 (m, 1H), 3.88−3.82 (m, 1H), 3.65 (s, 3H), 2.94 (s, 1H),
2.79 (s, 1H), 2.37 (t, J= 7.2Hz, 2H), 2.02−1.40 (m, 8H), 0.94 (t, J = 7.1
Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 174.3, 155.3, 147.3, 141.8,
140.0, 138.1, 130.0, 129.9, 129.1, 128.4, 125.4, 75.3, 74.2, 69.8, 51.8,
40.1, 33.8, 31.7, 21.3, 18.8, 14.0; IR (CHCl3) (νmax, cm
−1) 3020, 2976,
1734, 1216, 1095; [α]D = +27.63 (c = 1.2 in CHCl3); HRMS (ESI) [M
+ H]+ calcd 389.2076 for C21H29N2O5; found, 389.2096.
Methyl (5S,6R,E)-5,6-Dihydroxy-8-(3-((S)-1-hydroxybutyl)-
quinoxalin-2-yl)oct-7-enoate ((1S)-7). Acetonide (1S)-31 (28 mg,
0.065 mmol, 1 equiv) was dissolved in MeOH (1.5 mL),
camphorsulfonic acid (16 mg, 0.069 mmol, 1.05 equiv) was added,
and the reaction mixture was stirred at room temperature for 16 h The
mixture was diluted with Et2O (15 mL) and washed with H2O (10 mL)
and brine (10 mL), and the organic layer was dried with MgSO4,
filtered, and concentrated. The crude product was purified by
preparative thin-layer chromatography (96:4 CH2Cl2/MeOH). Prod-
uct (1S)-7 was isolated as a yellow oil (14 mg, 56%). Rf = 0.41 (96:4
CH2Cl2/MeOH);
1H NMR (400 MHz, CDCl3) δ 8.07−7.95 (m, 2H),
7.75−7.64 (m, 2H), 7.21 (dd, J = 15.5, 5.5Hz, 1H), 7.04 (d, J = 15.5Hz,
1H), 5.22−5.10 (m, 1H), 4.72−4.61 (m, 1H), 4.53−4.45 (m, 1H),
3.90−3.81 (m, 1H), 3.65 (s, 3H), 2.93−2.55 (m, 2H), 2.37 (t, J = 7.0
Hz, 2H), 1.96−1.67 (m, 4H), 1.59−1.48 (m, 4H), 0.95 (t, J = 7.0 Hz,
3H); 13C NMR (101 MHz, CDCl3) δ 174.2, 155.2, 147.2, 141.6, 139.8,
137.8, 129.8, 129.7, 128.9, 128.3, 125.2, 75.1, 74.0, 69.8, 51.6, 40.0,
33.6, 31.3, 21.1, 18.7, 13.9; IR (CHCl3) (νmax, cm
−1) 3020, 2976, 1734,
1216, 1095; [α]D =−60.02 (c = 1.4 in CHCl3); HRMS (ESI) [M +H]+
calcd 389.2076 for C21H29N2O5; found 389.2076.
1-(3-Bromoquinoxalin-2-yl)octan-1-one (28). 2-Bromoquinoxa-
line (350 mg, 1.67 mmol, 1 equiv) was dissolved in EtOAc (16 mL).
Octanal (1.05 mL, 6.715 mmol, 4 equiv) and TMSN3 (0.44 mL, 6.698
mmol, 2 equiv) were added. PhI(OCOCF3)2 (1.44 g, 6.698 mmol, 2
equiv) was added portionwise over 10 min, and the mixture turned
orange in color. The mixture was stirred at room temperature for 2 h.
Further, TMSN3 (0.44 mL, 6.698 mmol, 2 equiv) and PhI(OCOCF3)2
(1.44 g, 6.698 mmol, 2 equiv) were added and the reaction was stirred
for 18 h. Triethylamine (2 mL) was added dropwise, and the mixture
was stirred for 15 min. The reaction mixture was concentrated and the
crude mixture was purified by silica gel column chromatography (50:1
pentane/EtOAc) to afford product 28 as a yellow solid (259 mg, 61%).
Rf = 0.38 (10:1 cyclohexane/EtOAc); mp = 43−48 °C; 1H NMR (400
MHz, CDCl3) δ 8.16−8.04 (m, 2H), 7.90−7.81 (m, 2H), 3.18 (t, J = 7.5
Hz, 2H), 1.83−1.75 (m, 2H), 1.44−1.28 (m, 8H), 0.89 (t, J = 7.0 Hz,
3H); 13C NMR (101 MHz, CDCl3) δ 201.5, 149.8, 143.3, 139.6, 134.8,
132.6, 131.2, 129.8, 128.61, 40.7, 31.8, 29.3, 29.2, 23.7, 22.8, 14.2; IR
(CHCl3) (νmax, cm




ketone 28 (90 mg, 0.268 mmol, 1 equiv) was dissolved in iPrOH (3
mL). RuCl2[(S)-xylBinap][(S)-DAIPEN] (16 mg, 0.0134 mmol, 0.05
mmol), tBuOK (8 mg, 0.067 mmol, 0.25 equiv), and triisopropyl borate
(0.02 mL) were added, and the reaction mixture was stirred under 25
bar of H2 for 18 h. The mixture was concentrated and purified by silica
gel column chromatography (10:1 pentane/EtOAc), and product
(1R)-30 was isolated as a pale-yellow solid (37 mg, 41%). Mp = 48−54
°C; Rf = 0.41 (10:1 cyclohexane/EtOAc);
1H NMR (300 MHz,
CDCl3) δ 8.15−8.04 (m, 2H), 7.88−7.76 (m, 2H), 5.24−5.15 (m, 1H),
4.04 (d, J = 8.5 Hz, 1H), 2.13−2.01 (m, 1H), 1.65−1.57 (m, 3H), 1.29
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(s, 8H), 0.89 (t, J = 6.5 Hz, 3H); 13CNMR (101MHz, CDCl3) δ 157.0,
142.5, 139.7, 138.1, 130.7, 130.7, 128.5, 128.3, 71.4, 37.3, 31.8, 29.3,
29.2, 25.7, 22.6, 14.1; IR (CHCl3) (νmax, cm
−1) 3417, 1641; [α]D =
+12.48 (c = 1.7 in CHCl3); [M + H]
+ calcd 337.0915 for
C16H22N2O
79Br; found 337.0900; ee = 99% as determined by SFC
using a Chiralpak IC column (CO2/MeCN, gradient 99:1 0−1 min and
then gradient to 60:40 until 5 min, 3 mL/min), Rt = 3.43 min (S)-
enantiomer, 4.18 min (R)-enantiomer.
(S)-1-(3-Bromoquinoxalin-2-yl)octan-1-ol ((1S)-30). Quinoxaline
ketone 28 (100 mg, 0.298 mmol, 1 equiv) was dissolved in iPrOH (3
mL). RuCl2[(S)-xylBinap][(S)-DAIPEN] (18 mg, 0.0145 mmol, 0.05
mmol), tBuOK (8 mg, 0.0745 mmol, 0.25 equiv), and triisopropyl
borate (0.02 mL) were added, and the reaction mixture was stirred
under 25 bar of H2 for 18 h. The mixture was concentrated and purified
by silica gel column chromatography (10:1 pentane/EtOAc), and
product (1S)-30 was isolated as a pale-yellow solid (40 mg, 40%). [α]D
= −21.63 (c = 0.5 in CHCl3); ee = 98% as determined by SFC using a
Chiralpak IC column (CO2/MeCN, gradient 99:1 0−1 min and then
gradient to 60:40 until 5 min, 3 mL/min), Rt = 3.43 min (S)-
enantiomer, 4.18 min (R)-enantiomer; identical in all other physical
data to the previously prepared (1R)-enantiomer.
Methyl 4-((4S,5R)-5-((E)-2-(3-((R)-1-Hydroxyoctyl)quinoxalin-2-
yl)vinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)butanoate ((1R)-32).
Bis(benzonitrile)Pd(II)chloride (11 mg, 0.029 mmol, 0.15 equiv)
and dppb (21mg, 0.048mmol, 0.25 equiv) were dissolved in toluene (1
mL) and stirred at room temperature for 30min to give a creamy orange
solution. Quinoxaline alcohol (1R)-30 (65 mg, 0.193 mmol, 1 equiv),
dissolved in toluene (1 mL), and boronic ester 18 (81 mg, 0.231 mmol,
1.2 equiv), dissolved in toluene (1 mL), were added followed by EtOH
(0.09 mL) and Na2CO3 (0.22 mL of a 1 M aq solution, 0.222 mmol,
1.15 equiv). The reaction mixture was heated to 110 °C and stirred for
46 h. The reactionmixture was diluted withH2O (10mL) and extracted
with EtOAc (3 × 10 mL), and the extracts were washed with brine (15
mL), dried with MgSO4, filtered, and concentrated. The crude product
was purified by silica gel column chromatography (10:1 → 6:1
pentane/EtOAc) to give product (1R)-32 as a pale-yellow oil (38 mg,
40%). Rf = 0.19 (6:1 pentane/EtOAc);
1H NMR (400 MHz, CDCl3) δ
8.10−7.99 (m, 2H), 7.77−7.69 (m, 2H), 7.16 (dd, J = 15.0, 6.0 Hz,
1H), 6.99 (dd, J = 15.0, 1.0 Hz, 1H), 5.14 (td, J = 7.5, 3.0 Hz, 1H), 4.85
(td, J = 6.0, 1.0 Hz, 1H), 4.61 (d, J = 7.5 Hz, 1H), 4.31 (ddd, J = 9.0, 6.0,
5.0 Hz, 1H), 3.63 (s, 3H), 2.41−2.30 (m, 2H), 1.94−1.81 (m, 2H),
1.78−1.68 (m, 1H), 1.59 (s, 3H), 1.58−1.52 (m, 4H), 1.44 (s, 3H),
1.37−1.19 (m, 9H), 0.87 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz,
CDCl3) δ 173.9, 155.3, 147.0, 142.0, 140.0, 136.1, 129.9, 129.8, 129.3,
128.4, 125.5, 108.9, 78.5, 78.5, 70.0, 51.6, 38.3, 33.8, 31.9, 30.3, 29.5,
29.4, 28.4, 25.8, 25.7, 22.8, 22.0, 14.2; IR (CHCl3) (νmax, cm
−1) 3461,
2910, 1737, 1645, 1381; [α]D = +11.48 (c = 0.9 in CHCl3); HRMS
(ESI) [M + H]+ calcd 485.3015 for C28H41N2O5; found, 485.3017.
Methyl 4-((4S,5R)-5-((E)-2-(3-((S)-1-Hydroxyoctyl)quinoxalin-2-
yl)vinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)butanoate ((1S)-32).
Bis(benzonitrile)Pd(II)chloride (7 mg, 0.018 mmol, 0.15 equiv) and
dppb (13 mg, 0.03 mmol, 0.25 equiv) were dissolved in toluene (1 mL)
and stirred at room temperature for 30 min to give a creamy orange
solution. Quinoxaline alcohol (1S)-30 (40 mg, 0.119 mmol, 1 equiv),
dissolved in toluene (1 mL), and boronic ester 18 (57 mg, 0.161 mmol,
1.35 equiv), dissolved in toluene (1mL), were added followed by EtOH
(0.06 mL) and Na2CO3 (0.14 mL of a 1M aq solution, 0.14 mmol, 1.15
equiv). The reaction mixture was heated to 110 °C and stirred for 42 h.
The reaction mixture was diluted with H2O (10mL) and extracted with
EtOAc (3 × 10 mL), and the extracts were washed with H2O (10 mL)
and brine (15 mL), dried with MgSO4, filtered, and concentrated. The
crude product was purified by silica gel column chromatography (10:1
→ 3:1 pentane/EtOAc) to give product (1S)-32 as a pale-yellow oil (17
mg, 29%). Rf = 0.19 (6:1 pentane/EtOAc);
1H NMR (400 MHz,
CDCl3) δ 8.09−7.99 (m, 2H), 7.76− 7.68 (m, 2H), 7.17 (dd, J = 15.0,
6.0 Hz, 1H), 6.97 (dd, J = 15.0, 1.0 Hz, 1H), 5.15 (td, J = 7.5, 3.0 Hz,
1H), 4.86 (td, J = 6.5, 1.0 Hz, 1H), 4.68 (d, J = 7.5 Hz, 1H), 4.32 (dt, J =
8.0, 6.5 Hz, 1H), 3.62 (s, 3H), 2.43−2.27 (m, 2H), 1.93−1.82 (m, 2H),
1.78−1.69 (m, 1H), 1.59 (s, 3H), 1.57−1.51 (m, 5H), 1.44 (s, 3H),
1.32−1.24 (m, 8H), 0.86 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz,
CDCl3) δ 173.9, 155.3, 147.0, 142.0, 140.0, 136.0, 129.9, 129.9, 129.3,
128.4, 125.3, 108.9, 78.5, 78.5, 70.0, 51.7, 38.5, 33.8, 32.0, 30.4, 29.7,
29.4, 28.3, 25.9, 25.8, 22.8, 22.0, 14.2; IR (CHCl3) (νmax, cm
−1) 3461,
2910, 1737, 1645, 1381; [α]D = −75.51 (c = 0.9 in CHCl3); HRMS
(ESI) [M + H]+ calcd 485.3015 for C28H41N2O5; found, 485.2994.
Methyl (5S,6R,E)-5,6-Dihydroxy-8-(3-((R)-1-hydroxyoctyl)-
quinoxalin-2-yl)oct-7-enoate ((1R)-8). Acetonide (1R)-32 (33 mg,
0.068 mmol, 1 equiv) was dissolved in MeOH (1.5 mL),
camphorsulfonic acid (13 mg, 0.055 mmol, 0.8 equiv) was added,
and the reaction mixture was stirred at room temperature for 2 h.
Further, camphorsulfonic acid (13 mg, 0.055 mmol, 0.8 equiv) was
added and the reaction mixture was stirred for 1 h. The mixture was
concentrated and was purified by preparative thin-layer chromatog-
raphy (96:4 CH2Cl2/MeOH). Product (1R)-8 was isolated as a yellow
oil (11 mg, 37%). Rf = 0.31 (96:4 CH2Cl2/MeOH);
1H NMR (400
MHz, CDCl3) δ 8.06−7.97 (m, 2H), 7.74−7.67 (m, 2H), 7.24 (dd, J =
15.0, 5.5 Hz, 1H), 7.02 (dd, J = 15.0, 1.5 Hz, 1H), 5.18−5.11 (m, 1H),
4.63 (d, J = 7.0 Hz, 1H), 4.51−4.43 (m, 1H), 3.89−3.82 (m, 1H), 3.66
(s, 3H), 2.65 (s, 1H), 2.54 (s, 1H), 2.38 (t, J = 7.5 Hz, 2H), 1.95−1.84
(m, 2H), 1.81−1.66 (m, 2H), 1.63−1.52 (m, 4H), 1.29−1.21 (m, 8H),
0.85 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 174.1, 155.1,
147.0, 141.7, 139.9, 137.7, 129.8, 129.7, 129.0, 128.3, 125.3, 75.1, 74.0,
69.9, 51.6, 38.0, 33.6, 31.8, 31.4, 29.4, 29.2, 25.4, 22.6, 21.1, 14.1; IR
(CHCl3) (νmax, cm
−1) 3386, 3020, 2254, 1720, 1216; [α]D = +33.52 (c
= 0.7 in CHCl3); HRMS (ESI) [M + H]
+ calcd 445.2702 for
C25H37N2O5; found, 445.2704.
Methyl (5S,6R,E)-5,6-Dihydroxy-8-(3-((S)-1-hydroxyoctyl)-
quinoxalin-2-yl)oct-7-enoate ((1S)-8). Acetonide (1S)-32 (20 mg,
0.041 mmol, 1 equiv) was dissolved in MeOH (1.5 mL),
camphorsulfonic acid (8 mg, 0.034 mmol, 0.8 equiv) was added, and
the reaction mixture was stirred at room temperature for 3.5 h. The
mixture was concentrated and was purified by preparative thin-layer
chromatography (96:4 CH2Cl2/MeOH). Product (1S)-8 was isolated
as a yellow oil (7 mg, 39%). Rf = 0.31 (96:4 CH2Cl2/MeOH);
1HNMR
(400 MHz, CDCl3) δ 8.08−7.98 (m, 2H), 7.75−7.68 (m, 2H), 7.22
(dd, J = 15.0, 6.5 Hz, 1H), 7.03 (dd, J = 15.0, 1.5 Hz, 1H), 5.19−5.14
(m, 1H), 4.66 (d, J = 6.5 Hz, 1H), 4.54−4.45 (m, 1H), 3.91−3.80 (m,
1H), 3.66 (s, 3H), 2.58 (s, 1H), 2.47 (s, 1H), 2.37 (td, J = 7.0, 1.5 Hz,
2H), 1.94−1.84 (m, 2H), 1.81−1.65 (m, 2H), 1.61−1.51 (m, 4H),
1.31−1.23 (m, 8H), 0.86 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz,
CDCl3) δ 174.2, 155.2, 147.1, 141.7, 139.9, 137.7, 129.8, 129.7, 129.0,
128.3, 125.2, 75.1, 73.9, 70.0, 51.6, 38.0, 33.6, 31.8, 31.3, 29.4, 29.2,
25.5, 22.6, 21.0, 14.1; IR (CHCl3) (νmax, cm
−1) 3386, 3020, 2254, 1720,
1216; [α]D =−69.52 (c = 0.7 in CHCl3); HRMS (ESI) [M +H]+ calcd
445.2702 for C25H37N2O5; found, 445.2722.
Biology Materials and Methods. Materials. In Vitro Study.
THP-1monocytes were purchased from LGCPromochem (Middlesex,
U.K.). The Vybrant Phagocytosis Assay kit (V-6694) was obtained
from Molecular Probes. THP-1-Lucia nuclear factor (NF)-κB cells,
heat-killed Listeria monocytogenes (HKLM), Zeocin, Normocin,
QUANTI-Luc, Geneticin (G418), and Hygromycin were purchased
from Invivogen (CA); the Pierce BCA Protein Assay kit was from
Thermo Scientific (Ireland); the Human Pro-Inflammatory multi-Plex
Tissue Culture kit was from MSD (Maryland); and the cytotoxicity
detection kit was from Roche (Germany). Transfecting SMCs with an
NF-κB reporter plasmid pNF-κB-SEAP vector were purchased from
Takara/Clontech (Ireland). HEK-293-transfected and wild-type cell
lines were kindly provided by Actelion Pharmaceuticals Ltd. (Switzer-
land). For calcium measurement, sterile plates black-sided with
optically clear glass flat bottoms were purchased from Perkin Elmer
(U.K.). LXA4 1 was obtained from Calbiochem (U.K.), and
dexamethasone was from Sigma-Aldrich (Ireland).
In Vivo Studies. C57BL/6J mice were purchased from Charles River
(U.K.). Zymosan was obtained from Sigma-Aldrich (Ireland) and used
in both in vivo studies. Flow cytometry mAb’s were obtained from BD
Biosciences or eBioscience.
Methods. Study Design. In Vitro Screening. In this study, we
initially screened the quinoxaline-containing sLXms (QNX-sLXms) for
safety and anti-inflammatory bioactions using a THP-1 monocyte cell
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line. The eight candidate molecules screened were divided into four
groups, based on the synthetic strategy adopted (Figure 2).
• Group A: (R)- and (S)-epimers of the QNX derivatives display
an acetonide on the upper chain and maintain the lower chain of
the same length as the LXA4 native compound (six-carbon chain,
-6C-). We refer to them as (R)-17 and (S)-17.
• Group B: (R)- and (S)-epimers of the QNX derivatives display a
diol on the upper chain andmaintain the lower chain of the same
length as LXA4 (six-carbon chain, -6C-). We refer to them as
(R)-6 and (S)-6.
• GroupC: (R)- and (S)-epimers of theQNX derivatives display a
diol on the upper chain and shorten the lower chain of two
carbons compared to the native compound (four-carbon chain,
-4C-). We refer to them as (R)-7 and (S)-7.
• Group D: (R)- and (S)-epimers of the QNX derivatives display
a diol on the upper chain and extend the lower chain of two extra
carbons compared to the native compound (eight-carbon chain,
-8C-). We refer to them as (R)-8 and (S)-8.
Cell Culture. THP-1-Lucia Human Monocytes. Mycoplasma-free
THP-1-Lucia NF-κB cells were grown in an RPMI 1640 (Gibco)
medium containing 2 mM L-glutamine, 1.50 g/L sodium bicarbonate,
4.50 g/L glucose, 10 mM N-(2-hydroxyethyl)piperazine-N′-ethane-
sulfonic acid (HEPES), and 1 mM sodium pyruvate. Then, 10% heat-
inactivated fetal bovine serum (FBS) (30 min at 56 °C), 100 μg/mL
Normocin, and Pen-Strep (50 U/mL to 50 μg/mL) were also added to
the growth media. As THP-1-Lucia cells were resistant to Zeocin, the
latter was used as a selective antibiotic (a high dose, i.e., 100 μg/mL, was
alternated every 2 weeks with a low dose, i.e., 10 μg/mL).
LXA4 1 and all of the tested sLXms were dissolved in ethanol and
further diluted in a culture medium (final ethanol concentration 0.1%;
equivalent concentrations were used as the vehicle control). Prior to in
vitro experiments, THP-1-Lucia NF-κB cells were harvested and plated
at 1 × 105 cells/well on 96-well plates and left to settle in the incubator
at 37 °C, 95% humidity, and 5% CO2, in 0.1% FBS-containing media,
pretreated for 30 min with increasing doses of LXA4 1, sLXms (from
10−12 to 10−6M), or appropriate controls, followed by stimulation with
50 ng/mL LPS for 24 h. Untreated (Unt) or vehicle-treated (Veh) cells
were used as negative controls; 1 pM (1R)-5, the (1R)-epimer of the
benzo-mimetic, was used as a positive control for any aromatic mimetic;
and, finally, we compared the observed effects to the conventional
glucocorticoid dexamethasone (Dex) treatment, at 1 μM.
Notably, the same conditioned media was used for measuring NF-κB
activity, cytotoxicity, and cytokine levels, strengthening the power of
our findings.
THP-1 Human Monocytes and Derived Macrophages. Mycoplas-
ma-free THP-1 monocytes were grown in an RPMI 1640 (Gibco)
medium containing 2 mM L-glutamine, 2.00 g/L sodium bicarbonate,
and 2.00 g/L glucose. Then, 10% (v/v) heat-inactivated FBS (30min at
56 °C) and Pen-Strep (100 U/mL to 100 μg/mL) were supplemented
to the growth media.
Monocytes were used for the relevant assays or, alternatively, were
differentiated to anMF0macrophage over 4 days, using 16 nM phorbol
12-myristate 13-acetate [PMA; dissolved in 0.02% dimethyl sulfoxide
(DMSO)] for 48 h, followed by 24 h of resting, prior to replacement of
media containing 0.1% FBS and subsequent treatment with LXA4,
sLXms, or appropriate controls (see details ahead).
Mouse Primary Vascular Smooth Muscle Cells (SMCs). Mouse
primary vascular SMCs were cultured at 37 °C in a humidified
atmosphere of 95% air/5%CO2 andmaintained inDulbecco’s modified
Eagle’s medium (DMEM; Life Technologies) supplemented with 25
mmol/L glucose with 10% (v/v) FBS. For treatments, media contained
only 1% FBS. After serum restriction for 24 h, cells were stimulated with
LXA4, sLXms, or appropriate controls (see details ahead).
HEK-293 Human Embryonic Kidney. HEK-293-transfected and wt
cell lines were cultured in Dulbecco’s modified Eagle’s medium
(DMEMGlutamax, 4mM L-glu and 4.50 g/L glucoseGibco, Ireland)
supplemented with heat-inactivated (30 min at 56C) 10% (v/v) FBS
(Invitrogen, U.K.), 50 U penicillin, and 50 μg of streptomycin
(Invitrogen, U.K.). As stably double-transfected FPR2+/Gαq
+ HEK-
293 cells were resistant to Geneticin and Hygromycin, these were used
as selective antibiotics (500 and 100 μg/mL, respectively) to maintain
the stable double transfection with the ALX/FPR2 receptor and the
Gαq subunit coupled to it. Immediately prior to calcium measurement,
fluorescently labeled cells were treated with 10−11/−9/−7M LXA4 1 or
sLXms using an injection system coupled to the fluorescence reader.
Cell Treatment. For in vitro screening and in vivo testing, depending
on the specific assay requirements, the following treatments were used.
• Vehicle. 0.1% Ethanol (EtOH) was used as the vehicle control.
Highly concentrated LXA4 and sLXms were dissolved in pure
EtOH to make stocks and then were added to cells at the
required working concentration, keeping EtOH to a safe
concentration of 0.1%.
• ALX/FPR2 agonists. Depending on the specific assay, the native
compound LXA4 (within 1 pM−1 μM range) or W-peptide (2
nM) was used as the control for, respectively, endogenous or
exogenous ALX/FPR2 receptor agonism.
• TLR-dependent/-independent NF-κB pathway inducers. Depend-
ing on the specific assay, a series of inflammatory stimuli were
adopted to challenge in vitro monocytes or SMCs over 24 h.
Lipopolysaccharide (LPS) (50 ng/mL), an endotoxin expressed
on the outer cell membrane of Gram-negative bacteria, was used
to mimic a TLR-dependent infective/inflammatory stimulus.70
Tumor necrosis factor α (TNF-α) (1 ng/mL) was used to
mimic a TLR-independent and noninfective inflammatory
stimulus.71 Heat-killed Listeria monocytogenes (HKLM) (108
cells/mL) was selected as a positive control for TLR2 activity
and downstreamNF-κB activation, in an infective scenario.72 To
mimic in vivo TLR2-dependent NF-κB-driven acute and local
inflammation, mice were challenged with zymosan (1 mg/
mouse) to induce peritonitis73 or with carraggenan (50 μg/g) to
induce paw edema.74
• “Classical” anti-inf lammatory drugs. Dexametasone (Dex) (1
μM−1 μg/g) is a glucocorticoid used here in an in vitro/in vivo
control for anti-inflammatory activity.62 Naproxen is a classical
NSAID used here as an in vivo control for anti-inflammatory
activity.75
• Aromatic Lipoxin A4-mimetic. Benzo-lipoxin [2] (1 pM) is the
first LXA4 analogue asymmetrically synthesized
34 and is here
used as a control for any aromatic sLXm activity.
NFκB-Driven Luciferase Gene Reporter Assay in THP-1 Lucia
Monocytes. NFκB activity was monitored in the human THP-1
monocytic leukemia cell line containing a stably integrated NF-κB-
inducible Lucia reporter construct (as previously reported).21 When
stimulated with LPS, the transcription factor NF-κB is activated,
upregulating the synthesis of proinflammatory mediators, thus bringing
about an inflammatory response. In these cells, NF-κB activation is
linked to a firefly luciferase gene and can be measured using
luminescence.
Prior to in vitro experiments, THP-1-Lucia NF-κB cells were
pretreated for 30 min with increasing doses of native LXA4, quinoxaline
analogues (from 10−12 to 10−6 M), or appropriate controls, followed by
stimulation with LPS and incubation for 24 h. Heat-killed listeria
monocytogenes (HKLM) (108/mL) was used as a positive control.28
The levels of NF-κB-induced Luciferase were then measured in a
culture supernatant using QUANTI-Luc as the detection reagent, and
measurements were taken on a bioluminescence reader. The results are
reported as a % relative to LPS treatment, representing 100% luciferase
activity.
A total of 1 × 105 cells/well were treated in a 96-well plate as
mentioned above. After 24 h, the levels of NF-κB-induced Lucia were
assayed in a cell culture supernatant using QUANTI-Luc, as a detection
reagent, on a bioluminescence reader (Synergy HT, BioTek Instru-
ments, Inc. Vermont). Aliquots of the supernatant were retained for
subsequent cytokine and LDH assays. Cellular proteins were extracted
with a radioimmunoprecipitation assay (RIPA) buffer (Thermo Fisher,
Ireland), supplemented with protease inhibitors (Sigma-Aldrich,
Ireland). Lysates were clarified by centrifugation (3200g, 10’, 4 °C)
to remove cell debris, and the cell protein level was quantified by
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performing a bicinchoninic acid (BCA) assay (as per themanufacturer’s
instructions) reading the protein absorbance at 570 nm, using a
spectrophotometer (SPECTRAMAX M2, Molecular Devices (U.K.)
Limited). A “relative luminescence unit” (RLU) was obtained using the
average value of the lum/abs ratio of two replicates.
Multiplex Electrochemiluminescence Detection for Cytokine
Quantification. After 24 h of exposure to LXA4 1, sLXms, or vehicle,
followed by LPS stimulation (50 ng/mL), as described above, THP-1-
Lucia NF-κB-cell supernatants were collected and cleared by
centrifugation. Concentrations of IFN-γ, IL-1β, IL-6, IL-8, IL-10, IL-
12p70, and TNF-α in culture supernatants were assessed by electro-
chemi-luminescent detection, using a commercially available human
96-well plate “multiplex” (several analytes in the same well) kit for
tissue culture samples, according to the manufacturers’ guidelines.
Cytotoxicity Assay. Lactate dehydrogenase (LDH) was assayed in
cell supernatants to investigate possible cytotoxicity of the lead
compound. LDH is rapidly released into the culture medium after
disruption of the plasma membrane.67,69 After 24 h of exposure to
sLXms, vehicle, or controls, followed by LPS stimulation, as described
above, THP-1-Lucia NF-κB-cell supernatants were collected and LDH
was assayed. Cytotoxicity was evaluated relative to vehicle controls.
Maximum releasable LDH was determined in cells lysed with 2%
Triton-X-100 (Sigma-Aldrich, Ireland). LDH levels were assessed by
reading the absorbance at 490 nm (protein) and 690 nm (background
noise), using a spectrophotometer (SPECTRAMAX M2, Molecular
Devices (U.K.) Limited).
NFκB-Driven Luciferase Gene Reporter Assay on vSMCs. NF-κB
activity was assessed (as previously reported)18 by transfecting SMCs
with an NF-κB reporter plasmid (pNF-κB-SEAP vector; Takara/
Clontech) for 24 h and subsequently stimulating SMCs with TNF-α (1
ng/mL; R&D Systems) for 24 h in the presence or absence of the
vehicle (0.1% ethanol), LXA4 (0.1 nmol/L; Calbiochem), or (R)-6 (1
nmol/L). NF-κB activity was determined by measuring secreted
alkaline phosphatase in the culture supernatant using the SEAP
Reporter Gene Assay System (Roche Australia). Cell experiments were
performed six to eight times, and the values presented are the mean ±
SEM from independent experiments.
Phagocytosis Assay. After differentiation of THP-1 monocytes
(Mo) to macrophage (MF0) (48 h of PMA-trigger followed by 24 h of
resting), on day 4, 1 × 105 cells/well in 100 μL of 0.1% fetal calf serum
(FCS) containing RPMI media Mo or MF0 were plated (data not
shown). Cell adherence was allowed for 1 h and 30 min at 37 °C/5%
CO2. Cells were then treated for 30 min with controls and phagocytosis
effectors for testing (vehicle, LXs, Rvs, or sLXms). Subsequently, media
containing controls/effectors were vacuum-aspirated and replaced with
a solution containing fluorescently prelabeled E. coli-derived bio-
particles and cells were incubated in the dark for 2 h at 37 °C/5% CO2
to allow particle ingestion by monocytes/macrophages. After that,
media containing bioparticles were vacuum-aspirated and replaced with
a solution containing trypan blue and cells were incubated for 1 min at
room temperature to allow quenching of unbound particles to ensure
specificity of the fluorescent signal, deriving only from ingested particles
(not shown). After aspiration of Trypan, the fluorescence reading was
immediately performed at the following conditions: end point; reading
from the bottom of the plate; Ex.480/Em.520 nm.
In Vivo Peritonitis Model. Male C57BL/6J mice of 9 weeks of age
were purchased from Charles River (Kent, U.K.) and were housed in a
specific pathogen-free facility in individually ventilated and filtered
cages under positive pressure. Peritonitis was induced in mice by ip
injection of zymosan (purchased from Sigma-Aldrich; 1 mg per mouse
in 0.5 mL of phosphate-buffered saline (PBS)).73 Mice were treated
with dexamethasone (1 μg/g) purchased from Sigma-Aldrich 1 h prior
to zymosan injection or (R)-6 (2 and 6 ng/g) (200 μL IP) 30 min prior
to zymosan injection. Peritoneal cells were collected by lavage 4 h after
injection of zymosan. The local Animal Use and Care Committee and
The UK Home Office approved the animal experiments in accordance
with the derivatives of both The Home Office Guidance on the
Operation of Animals (Scientific Procedures) Act 1986 and The Guide
for the Care and Use of Laboratory Animals of the National Research
Council.
Flow Cytometry. Surface marker expression on peritoneal cells was
assessed by flow cytometry with data collection on a FACSCalibur
(Becton Dickinson). Data were analyzed with FlowJo analysis software
(Treestar Inc.). Cells were stained with AlexaFluor488 conjugated anti-
F4/80 (clone BM8; eBioscience); APC conjugated anti-CD11b (clone
M1/70; eBioscience) and Pacific blue conjugated anti-Ly6G (clone
1A8; BioLegend) antibodies. Prior to surface staining, peritoneal cells
were counted manually (Neubauer chamber) with Turks solution.
Using appropriate fluorescence minus one (FMO) controls, quadrants
were drawn, and data were plotted on logarithmic-scale density- or dot-
plots.
NB:
F4/80: murine macrophage marker
Siglec F: eosinophil marker
Ly6G: neutrophil PMN marker
CD11b: granulocytes, monocytes/macrophages, dendritic cells, NK
cells, and subsets of T- and B-cell (myeloid cells) marker
AF488: Alexa Fluor 488 (fluorochrome)
APC: Allophycocyanin (fluorochrome)
In Vivo Paw Edema Model. The most and the least potent and
efficient QNXs tested in this study (respectively, (R)-6 and (R)-17, 45
ng/mouse = 2 μg/kg, ip) or Naproxen (50 mg/kg, po) were
administered 30 min before the intrapaw injection of 1% carrageenan
into male C57bl/6 mice.57,74 Then, 50 μL of 1% carrageenan was
injected with an equivalent volume of saline injected into the
contralateral paw. Inflammation was presented as the difference in
paw thickness over time using gauge (POCO 2T; Kroeplin, GmbH,
Surrey, U.K.). Data are presented as mean ± SEM, n = 3 mice/
treatment group.
Intracellular Calcium Flux Assay. To explore the mechanism of
action through which the sLXm lead compound exerts the effects seen
here, its interaction with the ALX/FPR2 receptor was investigated and
agonist-induced intracellular calcium transients weremeasured using an
engineered cell line stably overexpressing the ALX/FPR2 receptor and
the Gαq subunit coupled to it (Figure S6). Wild-type HEK cells were
used as controls, to verify the specificity of the agonism toward ALX/
FPR2, as previously reported.36 Briefly, prior to cell plating, sterile 96-
well plates (black-sided with optically clear glass flat bottoms) were
PDL-coated overnight. Subsequently, 2 × 105 wild-type cells and
overexpressed cells/well were cultured for 18 h in DMEM complete
media (containing Ca2+ and Mg2+) to facilitate adherence prior to
labeling with Fluo-4 dye. After 1 h of incubation at 37 °C with Fluo-4,
cells were gently washed twice and placed in 100%Hanks’ balanced salt
solution (HBSS; 37 °C) before reading the fluorescence (485/535
nm), using a spectrophotometer conjugated with an injection system
(Clariostar BMG LABTECH plate reader), allowing addition to the
cells of controls (1 mM ATP, a GPCR purinergic agonist, 2 nM Wp, a
synthetic ALX/FPR2 agonist) or experimental treatments [10 pM, 1
nM, and 100 nM LXA4 1 or (R)-6].
During calcium flux measurement, the kinetic steps involved were
the following: the baseline fluorescent signal was measured for 20 s,
followed by 100 s immediately after agonist injection. Subsequently, 2%
Triton-X-100 was added to lyse the cells (monitoring for 20 s the
maximal release of calcium ions in the extracellular environment) and,
finally, 25 mM tetraacetic acid (EGTA) was added to chelate calcium
ions (monitoring for additional 20 s the minimal detection of calcium
ions in the extracellular environment) (Figure S7).
Statistical Analysis. For the human monocytic cell line, results were
expressed as mean ± SEM relative to the vehicle control. Experimental
points were performed in duplicate with a minimum of three
independent experiments. Statistical comparisons between controls vs
treated groups weremade by parametric Student’s unpaired t-test with a
two-tailed distribution, assuming equal or unequal variance (based on
the outcome of the “F test two sample for variances”).
Data were analyzed using the Prism 8.4.2 software program for
Windows (GraphPad software, San Diego, CA). Differences between
two groups were analyzed by two-tailed unpaired Student’s t-test and by
one-way ANOVA to assess differences between more than two groups
using a post-test, Holm−Sidak’s multiple-comparison post hoc test. A p
< 0.05 was considered significant. For the murine model, statistical
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analysis was performed using one-way ANOVA with the Newman−
Keuls multiple-comparison test. For both analyses, a value of p ≤ 0.05
was considered significant.
PD Score. For the in vitro assays, a PD analysis was conducted for the
tested molecules to determine the PD profile per se and relative to LXA4
(1). The “coding” of the heat-map indicates the arbitrary criteria to
assign points to each single PD component (efficacy = Imax or Emax;
potency = IC50 or EC50; slope = HS) to generate a final (aggregate)
relative PD score. If a single PD component was greater than the
reference level (x > 1), then the single-component relative score was
arbitrarily set to +1 (light green) or +2 (dark green). If a single PD
component was equal to the reference level (x = 1), then the single-
component relative score was arbitrarily set to 0 (gray). If a single PD
component was smaller than the reference level (x < 1), then the single-
component relative score was arbitrarily set to −1 (light red) or −2
(dark red). If the curve of a single PD component was best fitting to a
flat line (x = 0), then the single-component relative score was arbitrarily
set to −4 (purple) (Table S1).
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